Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder characterized by persistent, intrusive, and distressing thoughts, images, or urges (obsessions) and repetitive behaviors or mental acts (compulsions) performed to reduce the anxiety the obsessions provoke. The pathophysiology centers on dysfunction of cortico-striato-thalamo-cortical (CSTC) circuits, with contributions from serotonergic, glutamatergic, and dopaminergic neurotransmission. OCD affects roughly 1-3% of the population, typically begins in childhood or early adulthood, and follows a chronic course. In DSM-5 and ICD-11 it was moved out of the anxiety disorders into the new "obsessive-compulsive and related disorders" grouping, although MONDO still classifies it under anxiety disorder.
Ask a research question about Obsessive-Compulsive Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Obsessive-Compulsive Disorder:
name: Obsessive-Compulsive Disorder
creation_date: "2026-06-21T00:00:00Z"
category: Psychiatric
description: >-
Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder
characterized by persistent, intrusive, and distressing thoughts, images, or
urges (obsessions) and repetitive behaviors or mental acts (compulsions)
performed to reduce the anxiety the obsessions provoke. The pathophysiology
centers on dysfunction of cortico-striato-thalamo-cortical (CSTC) circuits,
with contributions from serotonergic, glutamatergic, and dopaminergic
neurotransmission. OCD affects roughly 1-3% of the population, typically
begins in childhood or early adulthood, and follows a chronic course. In
DSM-5 and ICD-11 it was moved out of the anxiety disorders into the new
"obsessive-compulsive and related disorders" grouping, although MONDO still
classifies it under anxiety disorder.
disease_term:
preferred_term: obsessive-compulsive disorder
term:
id: MONDO:0008114
label: obsessive-compulsive disorder
parents:
- Anxiety Disorder
- Mental Health Disorder
pathophysiology:
- name: Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
description: >-
OCD is associated with hyperactivity within cortico-striato-thalamo-cortical
(CSTC) loops, particularly involving the orbitofrontal cortex, anterior
cingulate cortex, caudate nucleus, and thalamus. Imbalance between the
direct ("go") and indirect ("stop") basal ganglia pathways is thought to
impair the ability to suppress intrusive thoughts and repetitive behaviors.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
locations:
- preferred_term: orbitofrontal cortex
term:
id: UBERON:0004167
label: orbitofrontal cortex
- preferred_term: anterior cingulate cortex
term:
id: UBERON:0009835
label: anterior cingulate cortex
- preferred_term: caudate nucleus
term:
id: UBERON:0001873
label: caudate nucleus
- preferred_term: thalamus
term:
id: UBERON:0001897
label: dorsal plus ventral thalamus
downstream:
- target: Impaired Inhibitory Control and Habit Formation
description: >-
CSTC hyperactivity is modeled upstream of impaired behavioral inhibition
and pathological habit formation.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Functional imaging studies in OCD show consistent evidence for increased
activity in brain regions that form a cortico-striato-thalamo-cortical
(CSTC) loop.
explanation: >-
Functional imaging evidence directly supports CSTC-loop hyperactivity as
the core circuit-level abnormality in OCD.
- reference: PMID:37137502
reference_title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
We show how dysfunction in cortico-striato-thalamo-cortical (CSTC)
circuits may underpin symptoms
explanation: >-
Review attributes OCD symptoms to CSTC circuit dysfunction.
- reference: PMID:17713528
reference_title: "Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
These findings demonstrate a critical role for SAPAP3 at cortico-striatal
synapses and emphasize the importance of cortico-striatal circuitry in
OCD-like behaviours.
explanation: >-
Genetic disruption of the cortico-striatal scaffolding protein SAPAP3 in
mice produces OCD-like behavior, providing causal support for
cortico-striatal circuit involvement.
- name: Dopaminergic Striatal Signaling
description: >-
Dopaminergic signaling, particularly within the striatum, is implicated in
OCD pathophysiology and in modulating compulsive behaviors. GWAS cell-type
enrichment associates D1- and D2-receptor-containing striatal medium spiny
neurons with OCD genetic risk.
biological_processes:
- preferred_term: dopamine receptor signaling pathway
term:
id: GO:0007212
label: G protein-coupled dopamine receptor signaling pathway
modifier: ABNORMAL
locations:
- preferred_term: striatum
term:
id: UBERON:0002435
label: striatum
downstream:
- target: Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
description: >-
Dopaminergic striatal signaling is represented upstream of circuit-level
dysfunction.
evidence:
- reference: PMID:37137502
reference_title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
shed light on the putative neurochemistry within these loops such as the
role of serotonin, dopamine, and glutamate systems
explanation: >-
Review implicates dopamine (alongside serotonin and glutamate) in the
neurochemistry of CSTC loops in OCD.
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD genetic risk was associated with excitatory neurons in the
hippocampus and the cortex, along with D1 and D2 type dopamine
receptor-containing medium spiny neurons.
explanation: >-
GWAS cell-type enrichment associates OCD genetic risk with dopaminergic
striatal medium spiny neurons; this is genetic-association evidence rather
than direct proof of dopaminergic causation.
- name: Serotonergic Neurotransmission Dysregulation
description: >-
Dysfunction of serotonergic signaling is implicated in OCD, supported by the
selective efficacy of serotonin reuptake inhibitors. Altered serotonin
receptor and transporter function modulates CSTC circuit activity.
biological_processes:
- preferred_term: serotonin receptor signaling pathway
term:
id: GO:0007210
label: serotonin receptor signaling pathway
modifier: ABNORMAL
downstream:
- target: Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
description: >-
Serotonergic dysregulation is represented upstream of circuit-level
dysfunction.
evidence:
- reference: PMID:37137502
reference_title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
shed light on the putative neurochemistry within these loops such as the
role of serotonin, dopamine, and glutamate systems
explanation: >-
Review implicates serotonin (alongside dopamine and glutamate) in the
neurochemistry of CSTC loops in OCD.
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
The preferential efficacy of SRIs in OCD has neither led to discovery of
serotonergic abnormalities in OCD nor to development of new serotonergic
medications for OCD.
explanation: >-
The selective efficacy of serotonin reuptake inhibitors implicates the
serotonin system, though direct serotonergic abnormalities remain
unproven — supporting serotonergic involvement only partially.
- name: Glutamatergic Signaling Imbalance
description: >-
Elevated glutamatergic neurotransmission within CSTC circuits, including
altered glutamate transporter (SLC1A1/EAAT3) function, contributes to
excitatory imbalance in OCD.
biological_processes:
- preferred_term: glutamate receptor signaling pathway
term:
id: GO:0007215
label: glutamate receptor signaling pathway
modifier: INCREASED
downstream:
- target: Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
description: >-
Glutamatergic imbalance is represented upstream of circuit-level
dysfunction.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Several lines of preclinical and clinical evidence suggest dysfunction of
the glutamatergic system in OCD, prompting testing of several promising
glutamate modulating agents.
explanation: >-
Preclinical and clinical evidence supports glutamatergic dysfunction as a
contributor to OCD pathophysiology.
- reference: PMID:28507136
reference_title: "OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
these findings indicate that the most consistently associated OCD
candidate gene impacts basal ganglia-dependent repetitive behaviors
explanation: >-
Disruption of the glutamate transporter gene Slc1a1/EAAT3 in mice alters
basal ganglia function and repetitive behavior, linking glutamatergic
transport to OCD-relevant circuitry.
- name: Impaired Inhibitory Control and Habit Formation
description: >-
The convergence of circuit and neurotransmitter abnormalities manifests as
impaired top-down inhibitory control and a shift toward inflexible,
habit-driven behavior, producing the obsessions and compulsions that
characterize OCD. Cognitive deficits in response inhibition, cognitive
flexibility, and goal-directed behavior are linked to aberrant CSTC
activity.
cell_types:
- preferred_term: neuron
term:
id: CL:0000540
label: neuron
biological_processes:
- preferred_term: regulation of behavior
term:
id: GO:0050795
label: regulation of behavior
modifier: ABNORMAL
evidence:
- reference: PMID:37137502
reference_title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
OCD is characterized by cognitive dysfunction including problems in
cognitive flexibility, visuospatial memory, response inhibition, and
goal-directed behavior, linked to aberrant activity within CSTC circuits
explanation: >-
Impaired response inhibition, cognitive flexibility, and goal-directed
behavior are tied to aberrant CSTC activity, supporting this node as the
behavioral output of circuit dysfunction.
phenotypes:
- name: Obsessions
description: >-
Recurrent, persistent, intrusive thoughts, urges, or images that are
experienced as unwanted and that cause marked anxiety or distress.
phenotype_term:
preferred_term: Obsessions
term:
id: HP:0008770
label: Obsessive-compulsive trait
evidence:
- reference: PMID:37859440
reference_title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
characterized by overwhelming obsessions and compulsions
explanation: >-
Clinical review of human OCD identifies obsessions as a defining feature.
- name: Compulsions
description: >-
Repetitive behaviors or mental acts that the individual feels driven to
perform in response to an obsession or according to rigid rules, aimed at
reducing anxiety or preventing a dreaded event.
phenotype_term:
preferred_term: Compulsions
term:
id: HP:0000722
label: Compulsive behaviors
evidence:
- reference: PMID:37859440
reference_title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
characterized by overwhelming obsessions and compulsions
explanation: >-
Clinical review of human OCD identifies compulsions as a defining feature.
- name: Anxiety
description: >-
Marked anxiety and distress provoked by obsessions and by resisting
compulsions.
phenotype_term:
preferred_term: Anxiety
term:
id: HP:0000739
label: Anxiety
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD shared genetic risk with anxiety, depression, anorexia nervosa and
Tourette syndrome
explanation: >-
Shared genetic risk between OCD and anxiety supports the close
relationship of anxiety with OCD; this is genetic-correlation evidence
rather than a direct measure of the anxiety phenotype.
- reference: PMID:20418887
reference_title: "Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
loss of a neuron-specific transmembrane protein, SLIT and NTRK-like
protein-5 (Slitrk5), leads to OCD-like behaviors in mice, which manifests
as excessive self-grooming and increased anxiety-like behaviors, and is
alleviated by the selective serotonin reuptake inhibitor fluoxetine
explanation: >-
The Slitrk5 OCD mouse model recapitulates increased anxiety-like behavior
alongside compulsive grooming.
- name: Cognitive dysfunction
category: Cognitive
description: >-
OCD is associated with cognitive deficits including impaired response
inhibition, reduced cognitive flexibility, and impaired goal-directed
behavior, linked to aberrant CSTC circuit activity.
phenotype_term:
preferred_term: Cognitive impairment
term:
id: HP:0100543
label: Cognitive impairment
evidence:
- reference: PMID:37137502
reference_title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
OCD is characterized by cognitive dysfunction including problems in
cognitive flexibility, visuospatial memory, response inhibition, and
goal-directed behavior, linked to aberrant activity within CSTC circuits
explanation: >-
Review documents OCD-associated cognitive dysfunction across multiple
executive domains.
- name: Impulsivity
category: Behavioral
description: >-
Impulsivity, particularly attentional impulsivity, is elevated in OCD and is
associated with the hoarding symptom dimension, reflecting overlap between
compulsive and impulsive features.
phenotype_term:
preferred_term: Impulsivity
term:
id: HP:0100710
label: Impulsivity
evidence:
- reference: PMID:33146050
reference_title: "Multifaceted impulsivity in obsessive-compulsive disorder with hoarding symptoms"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Attentional impulsivity is associated with hoarding symptoms in OCD.
explanation: >-
Study of 136 individuals with OCD links attentional impulsivity to the
hoarding dimension; supports impulsivity as a feature in a subset of OCD.
genetic:
- name: Polygenic Risk
association: Risk Factor
notes: >-
OCD is a heritable, polygenic disorder. A 2025 GWAS meta-analysis of 53,660
cases and 2,044,417 controls identified 30 independent genome-wide
significant loci and implicated excitatory neurons and dopaminergic medium
spiny neurons in genetic risk.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We conducted a genome-wide association study (GWAS) meta-analysis
combining 53,660 OCD cases and 2,044,417 controls and identified 30
independent genome-wide significant loci.
explanation: >-
Large GWAS meta-analysis establishes the polygenic genetic architecture
of OCD with 30 risk loci.
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD genetic risk was associated with excitatory neurons in the
hippocampus and the cortex, along with D1 and D2 type dopamine
receptor-containing medium spiny neurons.
explanation: >-
GWAS cell-type enrichment links OCD genetic risk to cortical excitatory
neurons and striatal dopaminergic medium spiny neurons, consistent with
the CSTC model.
- name: WDR6
gene_term:
preferred_term: WDR6
term:
id: hgnc:12758
label: WDR6
association: Risk Factor
notes: >-
WD repeat domain 6 (2q33); one of the most likely causal effector genes from
the 2025 OCD GWAS, prioritized by both TWAS-COLOC and SMR-HEIDI causal-support
filters.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
with 25 of these classified as the most likely causal candidates,
including WDR6, DALRD3 and CTNND1
explanation: >-
WDR6 is named among the most likely causal OCD effector genes in the
largest GWAS to date.
- name: DALRD3
gene_term:
preferred_term: DALRD3
term:
id: hgnc:25536
label: DALRD3
association: Risk Factor
notes: >-
DALR anticodon binding domain-containing 3 (2q33); prioritized as a likely
causal OCD effector gene by convergent causal-inference methods in the 2025
GWAS.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
with 25 of these classified as the most likely causal candidates,
including WDR6, DALRD3 and CTNND1
explanation: >-
DALRD3 is named among the most likely causal OCD effector genes in the
largest GWAS to date.
- name: CTNND1
gene_term:
preferred_term: CTNND1
term:
id: hgnc:2515
label: CTNND1
association: Risk Factor
notes: >-
Catenin delta-1 (6p22), a synaptic adhesion-related gene; implicated by
three orthogonal approaches (mBAT-combo, TWAS, PWAS) with colocalization
evidence, including protein downregulation in prefrontal cortex associated
with OCD risk.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
with 25 of these classified as the most likely causal candidates,
including WDR6, DALRD3 and CTNND1
explanation: >-
CTNND1 is named among the most likely causal OCD effector genes in the
largest GWAS to date.
- name: SLC1A1
gene_term:
preferred_term: SLC1A1
term:
id: hgnc:10939
label: SLC1A1
association: Risk Factor
notes: >-
Encodes the neuronal glutamate transporter EAAT3; variants have been
associated with OCD, implicating glutamatergic dysregulation in CSTC
circuits.
evidence:
- reference: PMID:28507136
reference_title: "OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
these findings indicate that the most consistently associated OCD
candidate gene impacts basal ganglia-dependent repetitive behaviors
explanation: >-
SLC1A1/EAAT3 is described as the most consistently associated OCD
candidate gene; its disruption in mice alters basal ganglia-dependent
repetitive behavior.
- name: SLITRK5
gene_term:
preferred_term: SLITRK5
term:
id: hgnc:20295
label: SLITRK5
association: Risk Factor
notes: >-
SLIT- and NTRK-like family member 5; Slitrk5-knockout mice display
compulsive grooming and corticostriatal abnormalities, modeling OCD-like
behavior.
evidence:
- reference: PMID:20418887
reference_title: "Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
loss of a neuron-specific transmembrane protein, SLIT and NTRK-like
protein-5 (Slitrk5), leads to OCD-like behaviors in mice, which manifests
as excessive self-grooming and increased anxiety-like behaviors, and is
alleviated by the selective serotonin reuptake inhibitor fluoxetine
explanation: >-
Slitrk5 loss in mice produces OCD-like compulsive grooming and anxiety
that responds to an SSRI, implicating the gene in corticostriatal OCD
pathophysiology.
- name: DLGAP3
gene_term:
preferred_term: DLGAP3 (SAPAP3)
term:
id: hgnc:30368
label: DLGAP3
association: Risk Factor
notes: >-
DLGAP3 encodes SAPAP3, a postsynaptic scaffolding protein at cortico-striatal
excitatory synapses highly expressed in the striatum. Sapap3-knockout mice
are a well-established model of OCD-like compulsive grooming.
evidence:
- reference: PMID:17713528
reference_title: "Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
mice with genetic deletion of Sapap3 exhibit increased anxiety and
compulsive grooming behaviour leading to facial hair loss and skin
lesions; both behaviours are alleviated by a selective serotonin reuptake
inhibitor
explanation: >-
Sapap3 (DLGAP3) deletion in mice recapitulates OCD-like compulsive
grooming and anxiety responsive to an SSRI, implicating cortico-striatal
synaptic dysfunction.
treatments:
- name: Selective Serotonin Reuptake Inhibitors
description: >-
SSRIs (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine) are first-line
pharmacotherapy for OCD, typically requiring higher doses and longer
duration than for depression.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: fluoxetine
term:
id: CHEBI:5118
label: fluoxetine
- preferred_term: sertraline
term:
id: CHEBI:9123
label: sertraline
target_mechanisms:
- target: Serotonergic Neurotransmission Dysregulation
treatment_effect: MODULATES
description: >-
SSRIs block presynaptic serotonin reuptake, increasing synaptic serotonin
and modulating serotonergic signaling within CSTC circuits.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The only established first-line treatments for OCD are exposure and
response prevention, and serotonin reuptake inhibitor medications (SRIs).
explanation: >-
Serotonin reuptake inhibitors are an established first-line
pharmacotherapy for OCD.
- name: Cognitive Behavioral Therapy with Exposure and Response Prevention
description: >-
CBT incorporating exposure and response prevention (ERP) is a first-line
psychotherapeutic treatment for OCD.
treatment_term:
preferred_term: cognitive behavior therapy
term:
id: MAXO:0000883
label: cognitive behavior therapy
target_mechanisms:
- target: Impaired Inhibitory Control and Habit Formation
treatment_effect: MODULATES
description: >-
Exposure and response prevention promotes inhibitory learning and fear
extinction, strengthening behavioral control over compulsions at the
behavioral output of CSTC dysfunction.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The only established first-line treatments for OCD are exposure and
response prevention, and serotonin reuptake inhibitor medications (SRIs).
explanation: >-
Exposure and response prevention is an established first-line treatment
for OCD.
- name: Antipsychotic Augmentation
description: >-
Adjunctive low-dose antipsychotic agents (e.g., risperidone, aripiprazole)
are added to serotonin reuptake inhibitors in partial responders, and are
the medication augmentation approach with the strongest empirical support
in OCD.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: risperidone
term:
id: CHEBI:8871
label: risperidone
- preferred_term: aripiprazole
term:
id: CHEBI:31236
label: aripiprazole
target_mechanisms:
- target: Dopaminergic Striatal Signaling
treatment_effect: MODULATES
description: >-
Antipsychotic augmentation modulates dopamine (D2) receptor signaling in
the striatum to reduce persistent compulsivity in SRI partial responders.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Beyond SRI monotherapy, antipsychotic augmentation is the only medication
approach for OCD with substantial empirical support.
explanation: >-
Antipsychotic augmentation of SRIs is the best-supported pharmacological
augmentation strategy for OCD.
- name: Deep Brain Stimulation
description: >-
Deep brain stimulation targeting nodes of the CSTC circuit is used for
severe, treatment-refractory OCD, providing further support for the CSTC
model.
therapeutic_modality: DEVICE
treatment_term:
preferred_term: deep brain stimulation
term:
id: MAXO:0000943
label: deep brain stimulation
target_mechanisms:
- target: Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
treatment_effect: MODULATES
description: >-
DBS delivers electrical modulation to CSTC nodes (e.g., ventral
capsule/ventral striatum), rebalancing pathologic frontostriatal network
activity.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Neuromodulation treatments with either noninvasive devices (e.g.,
transcranial magnetic stimulation) or invasive procedures (e.g., deep
brain stimulation) provide further support for the CSTC model of OCD.
explanation: >-
Deep brain stimulation is an established neuromodulation treatment for
refractory OCD that targets the CSTC circuit.
- name: Transcranial Magnetic Stimulation
description: >-
Repetitive/deep transcranial magnetic stimulation (TMS) is a noninvasive
neuromodulation therapy, FDA-cleared for OCD, that targets medial
prefrontal/anterior cingulate nodes of the CSTC circuit.
therapeutic_modality: DEVICE
treatment_term:
preferred_term: transcranial magnetic stimulation
term:
id: NCIT:C116655
label: Transcranial Magnetic Stimulation
target_mechanisms:
- target: Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
treatment_effect: MODULATES
description: >-
TMS noninvasively modulates dysfunctional frontostriatal/CSTC activity.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Neuromodulation treatments with either noninvasive devices (e.g.,
transcranial magnetic stimulation) or invasive procedures (e.g., deep
brain stimulation) provide further support for the CSTC model of OCD.
explanation: >-
Transcranial magnetic stimulation is a noninvasive neuromodulation
treatment for OCD targeting the CSTC circuit.
- name: Clomipramine
description: >-
Clomipramine, a serotonin-predominant tricyclic, was the first medication
proven effective in OCD and remains a potent serotonin reuptake inhibitor
option, typically reserved for SSRI non-responders due to its side-effect
profile.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: clomipramine
term:
id: CHEBI:47780
label: clomipramine
target_mechanisms:
- target: Serotonergic Neurotransmission Dysregulation
treatment_effect: MODULATES
description: >-
Clomipramine potently inhibits serotonin reuptake, modulating serotonergic
signaling within CSTC circuits.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The only established first-line treatments for OCD are exposure and
response prevention, and serotonin reuptake inhibitor medications (SRIs).
explanation: >-
Clomipramine is a serotonin reuptake inhibitor, the established
pharmacological class for OCD.
synonyms:
- obsessive compulsive disorder
- OCD
classifications:
harrisons_chapter:
- classification_value: NEUROLOGIC
mappings:
mondo_mappings:
- term:
id: MONDO:0008114
label: obsessive-compulsive disorder
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: Primary MONDO disease identifier for obsessive-compulsive disorder.
icd10cm_mappings:
- term:
id: ICD10CM:F42
label: Obsessive-compulsive disorder
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: MONDO cross-references ICD-10-CM F42 for obsessive-compulsive disorder.
ncit_mappings:
- term:
id: NCIT:C88411
label: Obsessive Compulsive Disorder
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: MONDO cross-references NCIT C88411 for obsessive-compulsive disorder.
prevalence:
- population: global (lifetime)
measure_type: LIFETIME_PREVALENCE
prevalence_class: ABOVE_1_IN_1000
rate_per_100000: 4100.0
percentage: 4.1
notes: World Mental Health surveys across 10 countries; literature range 1-3%.
evidence:
- reference: PMID:40629326
reference_title: "Obsessive-compulsive disorder in the World Mental Health surveys"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD has a combined lifetime prevalence of 4.1%. The 12-month prevalence
(3.0%) is nearly as high
explanation: >-
Cross-national surveys establish OCD lifetime prevalence at 4.1%.
- population: global (12-month)
measure_type: PERIOD_PREVALENCE
prevalence_class: ABOVE_1_IN_1000
rate_per_100000: 3000.0
percentage: 3.0
notes: Near-equal 12-month and lifetime prevalence indicates a highly persistent course.
evidence:
- reference: PMID:40629326
reference_title: "Obsessive-compulsive disorder in the World Mental Health surveys"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD has a combined lifetime prevalence of 4.1%. The 12-month prevalence
(3.0%) is nearly as high
explanation: >-
12-month prevalence (3.0%) nearly equals lifetime prevalence, reflecting
chronicity.
epidemiology:
- name: Age of onset
description: >-
OCD onset is early, with more than 80% of cases beginning by early
adulthood; onset is bimodal, peaking in adolescence and young adulthood.
evidence:
- reference: PMID:40629326
reference_title: "Obsessive-compulsive disorder in the World Mental Health surveys"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Age of onset is early, with more than 80% of OCD cases beginning by early
adulthood.
explanation: >-
Most OCD begins by early adulthood.
- name: Treatment gap
description: >-
OCD is widely undertreated; only about one in five affected individuals
receives any past-year mental health treatment, with a large high- versus
low/middle-income disparity.
evidence:
- reference: PMID:40629326
reference_title: "Obsessive-compulsive disorder in the World Mental Health surveys"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Only 19.8% of respondents with OCD received any mental health treatment in
the past year
explanation: >-
Quantifies the OCD treatment gap.
inheritance:
- name: Multifactorial (polygenic)
inheritance_term:
preferred_term: Polygenic inheritance
term:
id: HP:0010982
label: Polygenic inheritance
description: >-
OCD is a heritable, highly polygenic disorder; twin heritability is roughly
27-47% in adults and 45-65% in children, and common variants distributed
across thousands of loci account for most of the SNP-based heritability.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We estimated that ~11,500 genetic variants explained 90% of OCD genetic
heritability.
explanation: >-
Heritability distributed across ~11,500 variants establishes highly
polygenic inheritance.
progression:
- phase: Onset
age_range: 12-22
notes: Bimodal onset peaking in adolescence (12-14) and young adulthood (20-22).
evidence:
- reference: PMID:37859440
reference_title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
OCD typically starts in childhood or adolescence and persists throughout
life
explanation: >-
OCD typically begins in childhood or adolescence.
- phase: Chronic course
notes: Without treatment OCD persists throughout life with functional impairment.
evidence:
- reference: PMID:37859440
reference_title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
OCD typically starts in childhood or adolescence and persists throughout
life
explanation: >-
OCD follows a persistent, chronic course.
environmental:
- name: Streptococcal infection (PANDAS)
description: >-
In a subset of children, group A streptococcal infection is associated with
the abrupt onset of obsessive-compulsive symptoms and/or tics (pediatric
autoimmune neuropsychiatric disorders associated with streptococcal
infections, PANDAS), proposed to reflect an autoimmune/neuroinflammatory
mechanism. The diagnosis remains controversial.
evidence:
- reference: PMID:34778136
reference_title: "Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
are clinical conditions characterized by the sudden onset of
obsessive-compulsive disorder and/or tics
explanation: >-
PANDAS links streptococcal infection to acute-onset OCD in a subset of
children, an environmental/immune trigger.
diagnosis:
- name: Clinical DSM-5 diagnosis
presence: >-
Diagnosis is clinical, based on the presence of time-consuming obsessions
and/or compulsions that cause marked distress or functional impairment, with
a specifier for level of insight.
diagnosis_term:
preferred_term: clinical assessment
term:
id: MAXO:0000487
label: clinical assessment
evidence:
- reference: PMID:37137502
reference_title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
current diagnostic criteria, and common comorbidities
explanation: >-
Review describes standardized OCD diagnostic criteria.
- name: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
presence: >-
The Y-BOCS is the standard instrument for grading OCD symptom severity and
monitoring treatment response.
evidence:
- reference: PMID:40629326
reference_title: "Obsessive-compulsive disorder in the World Mental Health surveys"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Most OCD cases in the community are mild (47.0%) or very mild (27.5%),
with a smaller percentage designated as moderate (22.9%) or severe (2.7%)
by the Yale-Brown Obsessive-Compulsive Scale.
explanation: >-
Y-BOCS is used to grade OCD severity in epidemiological samples.
differential_diagnoses:
- name: Body dysmorphic disorder
description: >-
An obsessive-compulsive and related disorder featuring preoccupation with
perceived physical defects and related repetitive behaviors.
disease_term:
preferred_term: body dysmorphic disorder
term:
id: MONDO:0000690
label: body dysmorphic disorder
distinguishing_features:
- Preoccupations focus specifically on perceived appearance defects rather than broader obsessional themes.
evidence:
- reference: PMID:37859440
reference_title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
removed OCD from the anxiety disorder grouping and regrouped it into
obsessive-compulsive and related disorders
explanation: >-
Body dysmorphic disorder is part of the obsessive-compulsive and related
disorders spectrum distinguished from OCD.
- name: Trichotillomania
description: >-
A body-focused repetitive behavior disorder (hair-pulling) within the
obsessive-compulsive and related disorders spectrum.
disease_term:
preferred_term: trichotillomania
term:
id: MONDO:0013189
label: trichotillomania
distinguishing_features:
- Repetitive hair-pulling is not driven by obsessions and is typically not anxiety-reducing in the OCD sense.
evidence:
- reference: PMID:37859440
reference_title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
supports: SUPPORT
evidence_source: OTHER
snippet: >-
removed OCD from the anxiety disorder grouping and regrouped it into
obsessive-compulsive and related disorders
explanation: >-
Trichotillomania is part of the obsessive-compulsive and related disorders
spectrum distinguished from OCD.
- name: Tourette syndrome
description: >-
A tic disorder that frequently co-occurs with OCD and shares genetic risk,
but is defined by motor and vocal tics rather than obsessions/compulsions.
disease_term:
preferred_term: Tourette syndrome
term:
id: MONDO:0007661
label: Tourette syndrome
distinguishing_features:
- Defined by involuntary motor/vocal tics rather than obsession-driven compulsions.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD shared genetic risk with anxiety, depression, anorexia nervosa and
Tourette syndrome
explanation: >-
OCD shares genetic risk with Tourette syndrome, a key differential and
comorbidity.
- name: Generalized anxiety disorder
description: >-
A differential characterized by pervasive, excessive worry about everyday
matters rather than discrete intrusive obsessions and ritualized
compulsions.
disease_term:
preferred_term: generalized anxiety disorder
term:
id: MONDO:0001942
label: generalized anxiety disorder
distinguishing_features:
- Worries are about realistic life concerns and are not neutralized by compulsive rituals.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
OCD shared genetic risk with anxiety, depression, anorexia nervosa and
Tourette syndrome
explanation: >-
OCD shares genetic liability with anxiety disorders, a frequent
differential; the snippet supports the shared-risk relationship.
- name: Obsessive-compulsive personality disorder
description: >-
A personality disorder of perfectionism, orderliness, and control that is
ego-syntonic, distinct from the ego-dystonic obsessions and compulsions of
OCD.
disease_term:
preferred_term: obsessive-compulsive personality disorder
term:
id: MONDO:0001158
label: obsessive-compulsive personality disorder
distinguishing_features:
- Traits are ego-syntonic (experienced as appropriate) rather than ego-dystonic intrusive obsessions.
animal_models:
- species: Mouse
genotype: Sapap3 knockout (Sapap3-/-, Dlgap3-/-)
description: >-
Genetic deletion of Sapap3 (DLGAP3), a postsynaptic scaffolding protein at
cortico-striatal excitatory synapses, produces increased anxiety and
compulsive grooming with self-inflicted skin lesions and cortico-striatal
synaptic defects, reversible by an SSRI. A leading OCD mouse model.
evidence:
- reference: PMID:17713528
reference_title: "Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
mice with genetic deletion of Sapap3 exhibit increased anxiety and
compulsive grooming behaviour leading to facial hair loss and skin
lesions; both behaviours are alleviated by a selective serotonin reuptake
inhibitor
explanation: >-
Sapap3-knockout mice recapitulate compulsive grooming and anxiety
responsive to SSRIs.
- species: Mouse
genotype: Slitrk5 knockout (Slitrk5-/-)
description: >-
Loss of the synaptic transmembrane protein Slitrk5 causes excessive
self-grooming, increased anxiety, orbitofrontal overactivation, and striatal
abnormalities, alleviated by fluoxetine.
evidence:
- reference: PMID:20418887
reference_title: "Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
loss of a neuron-specific transmembrane protein, SLIT and NTRK-like
protein-5 (Slitrk5), leads to OCD-like behaviors in mice, which manifests
as excessive self-grooming and increased anxiety-like behaviors, and is
alleviated by the selective serotonin reuptake inhibitor fluoxetine
explanation: >-
Slitrk5-knockout mice model compulsive grooming and anxiety responsive to
an SSRI.
- species: Mouse
genotype: Slc1a1/EAAT3 loss (Slc1a1-STOP)
description: >-
Ablation of the OCD candidate glutamate transporter EAAT3 (Slc1a1) alters
basal ganglia-dependent repetitive behaviors and dopaminergic function,
linking the most consistently associated OCD candidate gene to striatal
circuitry.
evidence:
- reference: PMID:28507136
reference_title: "OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
these findings indicate that the most consistently associated OCD
candidate gene impacts basal ganglia-dependent repetitive behaviors
explanation: >-
Slc1a1/EAAT3 loss in mice alters basal ganglia-dependent repetitive
behavior.
- species: Mouse
genotype: Hoxb8 knockout (Hoxb8-/-)
description: >-
Hoxb8 mutant mice exhibit fully penetrant excessive grooming causing hair
removal and skin lesions, a pathological grooming phenotype likened to the
OC-spectrum disorder trichotillomania and traced to CNS (microglial)
abnormalities.
evidence:
- reference: PMID:11779477
reference_title: "Hoxb8 is required for normal grooming behavior in mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
mice with disruptions of Hoxb8 show, with 100% penetrance, excessive
grooming leading to hair removal and lesions.
explanation: >-
Hoxb8-knockout mice model pathological grooming relevant to OC-spectrum
behavior.
- species: Mouse
genotype: Optogenetic OFC-VMS hyperstimulation (wild-type)
category: Induced
description: >-
Repeated optogenetic hyperactivation of orbitofrontal cortex (OFC) to
ventromedial striatum (VMS) projections generates a progressive, persistent
increase in grooming, causally implicating CSTC corticostriatal
hyperactivity in OCD-like repetitive behavior.
evidence:
- reference: PMID:23744948
reference_title: "Repeated cortico-striatal stimulation generates persistent OCD-like behavior"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
repeated hyperactivation over multiple days generated a progressive
increase in grooming, a mouse behavior related to OCD
explanation: >-
Optogenetic OFC-VMS hyperstimulation causally produces persistent
OCD-like grooming, supporting the CSTC circuit model.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_cstc_serotonergic_glutamatergic
hypothesis_label: Canonical CSTC Circuit / Serotonergic-Glutamatergic Model
status: CANONICAL
description: >-
OCD arises from hyperactivity and imbalance within cortico-striato-thalamo-
cortical (CSTC) loops (orbitofrontal cortex, anterior cingulate cortex,
caudate, thalamus), shaped by serotonergic, glutamatergic, and dopaminergic
neurotransmission. The selective efficacy of serotonin reuptake inhibitors,
consistent functional-imaging evidence of CSTC hyperactivity, and benefit of
CSTC-targeted neuromodulation (TMS, deep brain stimulation) converge on this
model.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Functional imaging studies in OCD show consistent evidence for increased
activity in brain regions that form a cortico-striato-thalamo-cortical
(CSTC) loop.
explanation: >-
Imaging evidence for CSTC hyperactivity anchors the canonical model.
- hypothesis_group_id: emerging_neuroimmune_mhc
hypothesis_label: Emerging Neuroimmune / MHC Contribution
status: EMERGING
description: >-
Genome-wide association implicates the major histocompatibility complex
(MHC) region in OCD risk, and PANDAS links streptococcal infection to
acute-onset OCD, suggesting a neuroimmune/neuroinflammatory contribution
that remains to be mechanistically resolved.
evidence:
- reference: PMID:40360802
reference_title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
multiple genes in the major histocompatibility complex (MHC) region
explanation: >-
GWAS implication of the MHC region motivates a neuroimmune hypothesis,
though the causal mechanism is unresolved.
clinical_trials:
- name: NCT03299166
phase: PHASE_III
status: COMPLETED
description: >-
Randomized, double-blind, placebo-controlled Phase 2/3 trial of adjunctive
troriluzole (a glutamate-modulating prodrug of riluzole) in adults with OCD
and inadequate response to serotonergic pharmacotherapy, testing the
glutamatergic-dysregulation hypothesis therapeutically.
target_phenotypes:
- preferred_term: Obsessions and compulsions
term:
id: HP:0008770
label: Obsessive-compulsive trait
evidence:
- reference: clinicaltrials:NCT03299166
reference_title: "A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The purpose of this study is to evaluate the efficacy of troriluzole as
adjunctive therapy versus placebo in participants with obsessive
compulsive disorder (OCD) who had an inadequate response to selective
serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or
desvenlafaxine treatment
explanation: >-
Trial of an adjunctive glutamate modulator directly tests the
glutamatergic-imbalance mechanism in treatment-resistant OCD.
- name: NCT02229903
phase: NOT_APPLICABLE
status: COMPLETED
description: >-
Randomized, double-blind, multicenter, sham-controlled trial of deep
transcranial magnetic stimulation (dTMS) over medial prefrontal/anterior
cingulate cortex in OCD; the pivotal study supporting FDA clearance of dTMS
for OCD and a clinical test of the CSTC neuromodulation model.
target_phenotypes:
- preferred_term: Obsessions and compulsions
term:
id: HP:0008770
label: Obsessive-compulsive trait
evidence:
- reference: clinicaltrials:NCT02229903
reference_title: "A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The Brainsway DTMS study is a randomized, 10 week, double blind,
multi-center trial comparing active DTMS treatment to sham treatment.
explanation: >-
Sham-controlled multicenter dTMS trial tests CSTC-targeted neuromodulation
as a treatment for OCD.
- name: NCT03356483
phase: PHASE_I
status: COMPLETED
description: >-
Double-blind, placebo-controlled study of oral psilocybin in OCD, probing
serotonergic (5-HT2A) psychedelic modulation of OCD symptoms and its neural
correlates.
target_phenotypes:
- preferred_term: Obsessions and compulsions
term:
id: HP:0008770
label: Obsessive-compulsive trait
evidence:
- reference: clinicaltrials:NCT03356483
reference_title: "Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study aims to investigate the effects of oral psilocybin on OCD
symptomatology and provide the first evidence of the neural mechanism that
may mediate psilocybin's purported therapeutic effects on OCD.
explanation: >-
Psilocybin trial tests serotonergic 5-HT2A modulation as a novel
mechanism-based treatment for OCD.
discussions:
- discussion_id: gap_ocd_serotonergic_paradox
prompt: >-
Why are serotonin reuptake inhibitors preferentially effective in OCD when
no consistent primary serotonergic abnormality has been identified, and what
is the true molecular target of their anti-obsessional effect?
kind: KNOWLEDGE_GAP
status: OPEN
attaches_to:
- pathophysiology#Serotonergic Neurotransmission Dysregulation
- treatment#Selective Serotonin Reuptake Inhibitors
rationale: >-
The serotonergic hypothesis of OCD rests almost entirely on the selective
therapeutic response to SRIs (a "pharmacological dissection"), yet decades of
work have not localized a primary serotonergic lesion. This leaves the
mechanism by which SRIs reduce obsessions and compulsions — and whether it is
serotonergic at all rather than downstream CSTC-circuit remodeling —
unresolved.
evidence:
- reference: PMID:33384007
reference_title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The preferential efficacy of SRIs in OCD has neither led to discovery of
serotonergic abnormalities in OCD nor to development of new serotonergic
medications for OCD.
explanation: >-
A leading review states explicitly that SRI efficacy has not been
reconciled with any identified serotonergic abnormality, defining the gap.
- discussion_id: mismatch_ocd_animal_models_obsessions
prompt: >-
Do rodent compulsive-grooming knockout models (Sapap3, Slitrk5, Slc1a1)
faithfully model human OCD, given that they reproduce repetitive
compulsive-like motor behavior but cannot capture the intrusive obsessions,
symptom dimensions, and fluctuating insight that define the human disorder?
kind: HUMAN_MODEL_MISMATCH
status: OPEN
attaches_to:
- genetic#SLITRK5
- genetic#DLGAP3
- genetic#SLC1A1
- pathophysiology#Cortico-Striato-Thalamo-Cortical Circuit Dysfunction
rationale: >-
The strongest mechanistic evidence for cortico-striatal causation in OCD
comes from mouse knockouts that develop excessive grooming reversible by
SSRIs. However, grooming is a motor stereotypy; obsessions are
cognitive-affective phenomena with no clear rodent analog, and insight is
uniquely human. Whether these models inform the obsessional/cognitive core
of OCD — or only its compulsive motor output — is mechanistically
consequential for target validation.
proposed_experiments:
- experiment_id: exp_ocd_cross_species_cstc_alignment
name: Cross-species CSTC circuit readout alignment
description: >-
Map orbitofrontal-striatal activity signatures associated with
compulsive grooming in Sapap3/Slitrk5 mice onto task-based fMRI CSTC
signatures in human OCD to test whether the same circuit state underlies
rodent compulsions and human symptoms, distinguishing shared compulsive
circuitry from human-specific obsessional processing.
evidence:
- reference: PMID:20418887
reference_title: "Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice"
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
provide a new mouse model of OCD-like behaviors
explanation: >-
The model is explicitly described as reproducing OCD-"like" behaviors,
underscoring that it captures a behavioral analog rather than the full
human syndrome.
references:
- reference: PMID:33384007
title: "Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder"
- reference: PMID:37137502
title: "Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction"
- reference: PMID:40360802
title: "Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder"
- reference: PMID:37859440
title: "Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults"
- reference: PMID:40629326
title: "Obsessive-compulsive disorder in the World Mental Health surveys"
- reference: PMID:17713528
title: "Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice"
- reference: PMID:34778136
title: "Diagnostic Approach to Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections (PANDAS): A Narrative Review of Literature Data"
- reference: PMID:33146050
title: "Multifaceted impulsivity in obsessive-compulsive disorder with hoarding symptoms"
- reference: PMID:11779477
title: "Hoxb8 is required for normal grooming behavior in mice"
- reference: PMID:23744948
title: "Repeated cortico-striatal stimulation generates persistent OCD-like behavior"
Obsessive-Compulsive Disorder (OCD) is a neuropsychiatric condition characterized by unwanted obsessions (repetitive thoughts, images, or urges) and/or compulsions (repetitive behaviors or mental acts) that cause significant distress and functional impairment (jalal2023obsessive‐compulsivedisorderetiology pages 1-2, roh2023clinicaladvancesin pages 1-2). OCD affects approximately 1-3% of the general population, making it a common psychiatric disorder with substantial public health burden (jalal2023obsessive‐compulsivedisorderetiology pages 1-2, stein2025obsessivecompulsivedisorderin pages 1-2, strom2025genomewideanalysesidentify pages 1-2).
In the DSM-5 and ICD-11, OCD was reclassified from the anxiety disorder category to a new grouping called "Obsessive-Compulsive and Related Disorders" (OCRD), reflecting improved understanding of its distinct neurobiological substrates (jalal2023obsessive‐compulsivedisorderetiology pages 1-2, roh2023clinicaladvancesin pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3). This category includes hoarding disorder, body dysmorphic disorder, trichotillomania, and excoriation disorder (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
According to DSM-5, diagnosis requires the presence of obsessions and/or compulsions that are time-consuming (taking more than one hour per day) and cause significant distress or interfere with everyday activities including social and occupational functioning (jalal2023obsessive‐compulsivedisorderetiology pages 1-2). The DSM-5 includes a specifier for insight level, recognizing that patients vary from good/fair insight to absent insight or delusional beliefs (jalal2023obsessive‐compulsivedisorderetiology pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
OCD etiology involves a complex interplay of genetic vulnerability, environmental exposures, and neurobiological mechanisms (dhiman2025hereditarypatternsand pages 1-1, roh2023clinicaladvancesin pages 1-2, liu2023earlyidentificationand pages 1-2).
Genetic Risk Factors: OCD demonstrates substantial heritability. Twin-based heritability estimates range from 27-47% in adults and 45-65% in children, with pediatric-onset OCD showing higher genetic loading than adult-onset cases (dhiman2025hereditarypatternsand pages 1-1, strom2025genomewideanalysesidentify pages 1-2, liu2023earlyidentificationand pages 1-2). Family studies indicate genetic contribution of 35-50% (roh2023clinicaladvancesin pages 1-2).
The largest genome-wide association study (GWAS) meta-analysis to date, combining 53,660 OCD cases and 2,044,417 controls, identified 30 independent genome-wide significant loci (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 2-3). Key findings include: - Approximately 11,500 genetic variants explain 90% of OCD genetic heritability, indicating highly polygenic architecture (strom2025genomewideanalysesidentify pages 2-3) - SNP-based heritability estimated at 6.7% (SE 0.3%) assuming 1% population prevalence, with higher estimates in clinically ascertained samples (strom2025genomewideanalysesidentify pages 2-3) - Priority candidate genes include WDR6, DALRD3, and CTNND1, along with multiple genes in the major histocompatibility complex (MHC) region (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4)
Environmental Risk Factors: While specific environmental factors remain under investigation, adverse lifetime experiences may induce neurobiological adaptations within a genetic vulnerability window (roh2023clinicaladvancesin pages 1-2). The OCDTWIN project is systematically investigating environmental risk factors through discordant monozygotic twin pairs (dhiman2025hereditarypatternsand pages 1-1).
Gene-Environment Interactions: Limited direct evidence exists for specific gene-environment interactions in OCD, though the OCDTWIN study aims to isolate unique environmental risk factors in the causal pathway while controlling for genetic influences (dhiman2025hereditarypatternsand pages 1-1).
| Gene/Locus | Chromosome Location | Function/Description | Evidence Type (GWAS/TWAS/PWAS) | P-value or significance | Key Findings |
|---|---|---|---|---|---|
| OCD GWAS meta-analysis summary | Genome-wide | Large-scale common-variant architecture of OCD | GWAS | 30 independent genome-wide significant loci in 53,660 cases and 2,044,417 controls; 1,672 SNPs exceeded genome-wide significance; threshold P < 5×10⁻⁸ (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 2-3) | Largest reported OCD GWAS identified 30 loci, substantially expanding prior findings and supporting a highly polygenic architecture (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 2-3) |
| Polygenic architecture | Genome-wide | Aggregate common-variant contribution to OCD risk | GWAS / MiXeR | ~11,500 causal variants (SE 607) explain 90% of OCD SNP-based heritability (strom2025genomewideanalysesidentify pages 2-3) | Indicates OCD risk is distributed across thousands of variants rather than a few high-penetrance loci, consistent with complex polygenic inheritance (strom2025genomewideanalysesidentify pages 2-3) |
| SNP-based heritability | Genome-wide | Common-variant heritability estimate | GWAS | h²SNP 6.7% (SE 0.3%) overall assuming 1% prevalence; subgroup estimates higher in clinically ascertained samples; earlier published estimates ranged ~8.5% to 16%, with older reports up to 28–37% depending on design/assumptions (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 2-3) | Supports measurable but incomplete capture of total OCD heritability by common SNPs; twin-based heritability remains higher than SNP-based estimates (strom2025genomewideanalysesidentify pages 1-2) |
| Twin/family heritability | Genome-wide | Familial genetic contribution | Family/twin studies summarized in review | Adults ~27–47%; children ~45–65% (strom2025genomewideanalysesidentify pages 1-2); broader review notes genetic contribution ~35–50% (roh2023clinicaladvancesin pages 1-2) | Higher heritability in pediatric-onset OCD supports stronger genetic loading in early-onset presentations (strom2025genomewideanalysesidentify pages 1-2, liu2023earlyidentificationand pages 1-2) |
| WDR6 | 2q33 | WD repeat domain 6; prioritized likely causal effector gene | GWAS + gene prioritization + TWAS-COLOC/SMR-HEIDI | Among 25 genes prioritized as most likely causal; implicated by multiple methods (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4) | One of only two genes prioritized by both TWAS-COLOC and SMR-HEIDI filters, strengthening causal inference beyond positional association alone (strom2025genomewideanalysesidentify pages 3-4) |
| DALRD3 | 2q33 | DALR anticodon binding domain-containing 3; prioritized likely causal effector gene | GWAS + gene prioritization + TWAS-COLOC/SMR-HEIDI | Among 25 genes prioritized as most likely causal; implicated by multiple methods (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4) | Along with WDR6, one of the strongest cross-method priority genes, supported by convergent colocalization/causality filters (strom2025genomewideanalysesidentify pages 3-4) |
| CTNND1 | 6p22 | Catenin delta-1; adhesion/synaptic-related gene, prioritized candidate | GWAS + TWAS + PWAS + colocalization | CTNND1 protein downregulation in human dlPFC associated with OCD risk: Z = -4.49, P = 7.11×10⁻⁶; TWAS in prefrontal cortex: Z = -6.86, P = 6.90×10⁻¹² (strom2025genomewideanalysesidentify pages 3-4) | Especially notable because it was implicated by three orthogonal approaches (mBAT-combo, TWAS, PWAS) and also showed evidence for colocalization, making it one of the most biologically convergent OCD genes (strom2025genomewideanalysesidentify pages 3-4) |
| MHC region / 6p21.33 locus | 6p21.33 | Major histocompatibility complex region; dense immune-related locus | GWAS | Lead SNP rs4990036, P = 1.45×10⁻¹¹; 118 genes within regional window (strom2025genomewideanalysesidentify pages 2-3) | MHC-region signal suggests possible neuroimmune contribution to OCD biology, although fine-mapping is challenging because of high linkage disequilibrium and gene density (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 2-3) |
| rs78587207 locus | 11q12.1 | Genome-wide significant lead SNP region | GWAS | P = 5.28×10⁻¹² (strom2025genomewideanalysesidentify pages 2-3) | One of the strongest individual loci in the meta-analysis; also overlaps signals seen in schizophrenia, well-being, neuroticism, and educational attainment databases (strom2025genomewideanalysesidentify pages 2-3) |
| rs13262595 locus | 8q24.3 | Genome-wide significant lead SNP region | GWAS | P = 1.31×10⁻¹¹ (strom2025genomewideanalysesidentify pages 2-3) | Strong association signal with cross-trait overlap including schizophrenia, neuroticism, and educational attainment, highlighting pleiotropy (strom2025genomewideanalysesidentify pages 2-3) |
| rs10877425 locus | 12q14.1 | Genome-wide significant lead SNP region | GWAS | P = 1.62×10⁻¹¹ (strom2025genomewideanalysesidentify pages 2-3) | High-confidence OCD locus without a highlighted nearby gene in the summary table, illustrating that some strong associations remain functionally unresolved (strom2025genomewideanalysesidentify pages 2-3) |
| rs7626445 locus | 3p21.31 | Genome-wide significant lead SNP region | GWAS | P = 1.74×10⁻¹¹ (strom2025genomewideanalysesidentify pages 2-3) | Associated region overlaps neuroticism, smoking, blood cell count, and height traits, again indicating polygenic pleiotropy (strom2025genomewideanalysesidentify pages 2-3) |
| rs2564930 locus | 3p21.1 | Genome-wide significant lead SNP region | GWAS | P = 3.41×10⁻¹¹ (strom2025genomewideanalysesidentify pages 2-3) | Strong signal in a region also linked to schizophrenia, neuroticism, blood cell count, and BMI (strom2025genomewideanalysesidentify pages 2-3) |
| rs4702 locus | 15q26.1 | Genome-wide significant lead SNP region | GWAS | P = 9.07×10⁻¹⁰ (strom2025genomewideanalysesidentify pages 2-3) | Notable because the same locus shows associations with bipolar disorder, major depressive disorder, and risk-taking behavior, consistent with shared psychiatric liability (strom2025genomewideanalysesidentify pages 2-3) |
| Gene-based discovery summary | Genome-wide | Aggregated gene-level prioritization from multiple methods | mBAT-combo / TWAS / SMR / PWAS / PsyOPS | 251 genes significant in at least one gene-based method; 48 genes implicated by ≥2 methods; 25 genes passed additional causal-support filters (strom2025genomewideanalysesidentify pages 2-3, strom2025genomewideanalysesidentify pages 3-4) | Multi-method integration greatly narrowed the candidate list from hundreds of genes to a smaller set of more plausible effector genes for functional follow-up (strom2025genomewideanalysesidentify pages 2-3, strom2025genomewideanalysesidentify pages 3-4) |
| Tissue enrichment | Brain tissues | Regional expression enrichment of OCD-associated genes | MAGMA / LDSC | Enrichment seen in anterior cingulate cortex, frontal cortex, cortex, nucleus accumbens, hippocampus, caudate, putamen, hypothalamus, substantia nigra, cerebellum and related brain tissues (strom2025genomewideanalysesidentify pages 3-4) | Supports a brain-circuit model centered on cortico-striatal and limbic systems rather than a diffuse whole-body signal (strom2025genomewideanalysesidentify pages 3-4, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Cell-type enrichment | Hippocampus, cortex, striatum | Neuronal cell classes implicated by genetic risk | Single-cell enrichment from GWAS signals | Significant enrichment in excitatory neurons in hippocampus/cortex and D1/D2 dopamine receptor-containing medium spiny neurons in striatum (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4) | Provides cell-type specificity linking OCD genetic risk to excitatory cortical/hippocampal neurons and striatal medium spiny neurons, consistent with CSTC circuit models (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Cross-trait genetic correlations | Genome-wide | Shared inherited liability with other disorders/traits | GWAS genetic correlation | OCD shared genetic risk with 65 of 112 phenotypes; especially anxiety, depression, anorexia nervosa, Tourette syndrome; negative associations with inflammatory bowel diseases, educational attainment, and BMI (strom2025genomewideanalysesidentify pages 1-2) | Reinforces that OCD genetics overlap substantially with other psychiatric phenotypes while also showing inverse relationships with some immune/metabolic traits (strom2025genomewideanalysesidentify pages 1-2) |
| Ascertainment and heterogeneity analyses | Genome-wide | Robustness of results across cohorts | GWAS / GenomicSEM | No statistically significant heterogeneity across the 30 lead loci by Cochran’s Q; moderate-to-high genetic correlations across ascertainment subgroups (strom2025genomewideanalysesidentify pages 2-3) | Suggests that major loci are broadly consistent across different OCD cohorts, even though ascertainment strategy influences genome-wide architecture to some extent (strom2025genomewideanalysesidentify pages 2-3) |
Table: This table summarizes the major genetic findings for obsessive-compulsive disorder from recent large-scale GWAS and gene-prioritization analyses. It highlights the most important loci, candidate genes, heritability estimates, and polygenic architecture features that are most useful for a disease knowledge base.
OCD symptoms are classified into partially distinct subtypes (jalal2023obsessive‐compulsivedisorderetiology pages 2-3): 1. Contamination fears and compulsive cleaning 2. Obsessive thoughts about causing harm and compulsive checking 3. Obsessions with symmetry and compulsive ordering 4. Obsessions with collecting and compulsive hoarding (now a separate disorder in DSM-5) 5. Purely obsessional subtype with unwanted thoughts about sex, violence, and blasphemy
Suggested HPO Terms: - HP:0000722 (Obsessive-compulsive behavior) - HP:0000733 (Repetitive compulsive behavior) - HP:0000723 (Restricted interests)
Age of Onset: OCD demonstrates a bimodal onset with peaks at 12-14 years and 20-22 years (liu2023earlyidentificationand pages 1-2). More than 80% of OCD cases begin by early adulthood (stein2025obsessivecompulsivedisorderin pages 1-2). Half of adult patients exhibited symptoms starting in childhood or adolescence (farrell2023closingthegap pages 1-2, liu2023earlyidentificationand pages 1-2).
Severity: In community samples, most OCD cases are mild (47.0%) or very mild (27.5%), with smaller percentages designated as moderate (22.9%) or severe (2.7%) by Yale-Brown Obsessive-Compulsive Scale (stein2025obsessivecompulsivedisorderin pages 1-2).
Progression: OCD typically starts in childhood or adolescence and often persists throughout life, causing functional impairment across multiple domains (roh2023clinicaladvancesin pages 1-2). The 12-month prevalence (3.0%) is nearly as high as lifetime prevalence (4.1%), suggesting highly persistent course (stein2025obsessivecompulsivedisorderin pages 1-2).
OCD causes substantial disability and is among the leading causes of illness-related burden according to the World Health Organization (roh2023clinicaladvancesin pages 1-2, farrell2023closingthegap pages 1-2). Childhood onset is associated with greater OCD severity, more symptoms, higher comorbidity, and poorer prognosis relative to adult onset (farrell2023closingthegap pages 1-2).
The 2025 GWAS meta-analysis identified 249 potential effector genes for OCD, with 25 classified as most likely causal candidates (strom2025genomewideanalysesidentify pages 1-2). Key genes include:
The current evidence primarily derives from common variant GWAS rather than rare coding variants. The polygenic architecture suggests thousands of small-effect variants rather than high-penetrance mutations (strom2025genomewideanalysesidentify pages 2-3).
OCD genetic risk shows significant enrichment in: - Excitatory neurons in hippocampus and cerebral cortex - D1 and D2 type dopamine receptor-containing medium spiny neurons in the striatum (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4)
Tissue enrichment analysis revealed significant signals in anterior cingulate cortex, frontal cortex, nucleus accumbens, hippocampus, caudate, putamen, hypothalamus, and cerebellum (strom2025genomewideanalysesidentify pages 3-4).
The specific environmental contributors to OCD remain under active investigation. The OCDTWIN project is systematically evaluating early life exposures including perinatal variables, psychosocial stressors, and health-related information through register linkages (dhiman2025hereditarypatternsand pages 1-1).
Limited specific data available from retrieved sources.
The dominant pathophysiological model implicates dysfunction in cortico-striato-thalamo-cortical (CSTC) circuits (jalal2023obsessive‐compulsivedisorderetiology pages 1-2, roh2023clinicaladvancesin pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3). These parallel circuits are responsible for reward and motivational processes, executive function, motor and response inhibition, and habit-based behavior (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
Key CSTC circuits include (jalal2023obsessive‐compulsivedisorderetiology pages 2-3): 1. Affective circuit: Projects from anterior cingulate cortex (ACC) and ventromedial prefrontal cortex (vmPFC) to nucleus accumbens, involved in emotion and reward processing 2. Dorsal cognitive circuit: Projects from dorsolateral prefrontal cortex (dlPFC) to caudate nucleus, pertinent to executive function and working memory 3. Ventral cognitive circuit: Projects from anterolateral orbitofrontal cortex to putamen, responsible for motor and response inhibition 4. Sensorimotor circuit: Projects from premotor cortical regions to putamen, involved in habit-based behavior
Serotonin: Dysfunction in serotonergic neurotransmission is strongly implicated, as evidenced by the efficacy of selective serotonin reuptake inhibitors (SSRIs) (roh2023clinicaladvancesin pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
Dopamine: Dopaminergic systems play an important role, particularly in striatal function and the generation of compulsive behaviors (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
Glutamate: Glutamatergic dysregulation within CSTC circuits is increasingly recognized as contributing to OCD pathophysiology (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
OCD involves aberrant activity within CSTC circuits, with evidence of overactivity in orbitofrontal cortex and striatum that can normalize following successful pharmacological and psychological treatment (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
Suggested GO Terms: - GO:0007165 (Signal transduction) - GO:0007268 (Chemical synaptic transmission) - GO:0042493 (Response to drug) - GO:0050890 (Cognition)
Suggested CL Terms: - CL:0000540 (Neuron) - CL:0000100 (Motor neuron) - CL:0000679 (Glutamatergic neuron)
Primary Organs: Central nervous system, particularly brain regions within CSTC circuits
Brain Systems: - Orbitofrontal cortex (OFC) - Anterior cingulate cortex (ACC) - Dorsolateral prefrontal cortex (dlPFC) - Ventromedial prefrontal cortex (vmPFC) - Striatum (caudate nucleus, putamen, nucleus accumbens) - Thalamus - Cerebellum (jalal2023obsessive‐compulsivedisorderetiology pages 2-3, strom2025genomewideanalysesidentify pages 3-4)
Cell Types Affected: - Excitatory neurons in hippocampus and cortex - D1 and D2 dopamine receptor-containing medium spiny neurons in striatum (strom2025genomewideanalysesidentify pages 1-2, strom2025genomewideanalysesidentify pages 3-4)
Suggested UBERON Terms: - UBERON:0000955 (Brain) - UBERON:0002037 (Cerebellum) - UBERON:0001950 (Neocortex) - UBERON:0002435 (Striatum) - UBERON:0001897 (Thalamus)
Typical Age of Onset: Bimodal distribution with peaks at 12-14 years and 20-22 years (liu2023earlyidentificationand pages 1-2). More than 80% of cases begin by early adulthood, with more than half of adult OCD patients having onset in childhood or adolescence (stein2025obsessivecompulsivedisorderin pages 1-2, farrell2023closingthegap pages 1-2).
Onset Pattern: Can be acute, subacute, or insidious. Childhood-onset OCD is associated with greater severity and higher genetic loading compared to adult-onset (farrell2023closingthegap pages 1-2, liu2023earlyidentificationand pages 1-2).
Disease Course: OCD typically demonstrates a chronic course with high persistence. The 12-month prevalence (3.0%) nearly equals lifetime prevalence (4.1%), suggesting minimal spontaneous remission (stein2025obsessivecompulsivedisorderin pages 1-2). Studies in youth suggest a higher percentage have an episodic course compared to adults (liu2023earlyidentificationand pages 1-2).
Duration: Delayed diagnosis is common, with a gap between onset and diagnosis of approximately 7-10 years in adults and more than 2 years in children (liu2023earlyidentificationand pages 1-2). Australian data suggest more than 9 years of untreated illness for OCD (farrell2023closingthegap pages 1-2).
Prevalence: Lifetime prevalence across 10 countries in World Mental Health surveys is 4.1%, with 12-month prevalence of 3.0% (stein2025obsessivecompulsivedisorderin pages 1-2). Estimates from literature range from 1-3% of the general population (jalal2023obsessive‐compulsivedisorderetiology pages 1-2, strom2025genomewideanalysesidentify pages 1-2).
Incidence: Pediatric-onset OCD affects approximately 2-4% of children and adolescents (liu2023earlyidentificationand pages 1-2).
OCD demonstrates polygenic inheritance with moderate heritability. Twin-based heritability: 27-47% in adults, 45-65% in children (dhiman2025hereditarypatternsand pages 1-1, strom2025genomewideanalysesidentify pages 1-2). Family studies show OCD is more prevalent in first-degree relatives of affected individuals (farrell2023closingthegap pages 1-2).
Age Distribution: Bimodal onset with peaks in adolescence (12-14 years) and young adulthood (20-22 years) (liu2023earlyidentificationand pages 1-2).
Sex Ratio: Available sources did not provide definitive male:female ratios.
Geographic Distribution: OCD appears cross-culturally prevalent with relatively consistent rates across high-income countries (HICs) and low-middle income countries (LMICs), though treatment rates are much higher in HICs (40.5%) than LMICs (7.0%) (stein2025obsessivecompulsivedisorderin pages 1-2).
DSM-5 Diagnostic Criteria: Presence of obsessions and/or compulsions that are time-consuming (>1 hour/day) and cause significant distress or functional impairment. Symptoms must not be attributable to other mental or physical disorders (jalal2023obsessive‐compulsivedisorderetiology pages 1-2).
Differential Diagnosis: Must distinguish from other obsessive-compulsive and related disorders, anxiety disorders, and psychotic disorders. Level of insight distinguishes OCD with poor/absent insight from primary psychotic illness (jalal2023obsessive‐compulsivedisorderetiology pages 1-2).
Severity Assessment: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) is the standard severity measure (stein2025obsessivecompulsivedisorderin pages 1-2).
Imaging Studies: Neuroimaging reveals functional abnormalities in CSTC circuits, particularly in orbitofrontal cortex, anterior cingulate cortex, striatum, and thalamus (jalal2023obsessive‐compulsivedisorderetiology pages 2-3). Both structural MRI and functional MRI demonstrate aberrant CSTC connectivity and activity (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
While specific genes have been identified through GWAS, genetic testing is not currently part of routine clinical diagnosis given the highly polygenic architecture. Research applications include whole exome sequencing and genome-wide genotyping for risk prediction and mechanistic studies (strom2025genomewideanalysesidentify pages 1-2).
OCD is highly persistent, with 12-month prevalence nearly matching lifetime prevalence (stein2025obsessivecompulsivedisorderin pages 1-2). The condition causes substantial functional impairment across academic, occupational, and social domains (farrell2023closingthegap pages 1-2). Childhood onset is associated with greater severity, more symptoms, and poorer prognosis than adult onset (farrell2023closingthegap pages 1-2).
OCD is ranked among the leading causes of illness-related disability by the World Health Organization (roh2023clinicaladvancesin pages 1-2). The disorder significantly impacts daily functioning, with severe cases experiencing substantial disability in occupational and social domains (farrell2023closingthegap pages 1-2).
Only 19.8% of respondents with OCD in World Mental Health surveys received any mental health treatment in the past year (stein2025obsessivecompulsivedisorderin pages 1-2). Approximately 50% of OCD patients do not respond adequately to initial treatments (huang2025advancingobsessive–compulsivedisorder pages 1-2). Treatment adherence during exposure and response prevention predicts both short-term and long-term outcomes (farrell2023closingthegap pages 1-2).
First-Line: Selective serotonin reuptake inhibitors (SSRIs) including fluoxetine, sertraline, fluvoxamine, paroxetine, and escitalopram are considered first-line pharmacotherapy (roh2023clinicaladvancesin pages 1-2, huang2025advancingobsessive–compulsivedisorder pages 1-2). SSRIs modulate serotonergic neurotransmission and downstream CSTC circuit activity (roh2023clinicaladvancesin pages 1-2).
Augmentation: Atypical antipsychotics are used for augmentation in SSRI partial responders, particularly those with tic-related presentations (roh2023clinicaladvancesin pages 1-2).
Cognitive Behavioral Therapy with Exposure and Response Prevention (CBT-ERP): Gold-standard psychological treatment involving systematic exposure to obsessional triggers with prevention of compulsive responses (roh2023clinicaladvancesin pages 1-2, farrell2023closingthegap pages 1-2). CBT-ERP promotes inhibitory learning, fear extinction, and improved cognitive control (farrell2023closingthegap pages 1-2).
Treatment Modalities: Delivered through individual therapy, family-based approaches, group therapy, and internet-delivered formats. Intensive or concentrated ERP (over consecutive days) may be beneficial for severe or treatment-resistant cases (farrell2023closingthegap pages 1-2).
Neuromodulation: Transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) targeting CSTC circuit nodes are used for treatment-refractory OCD (roh2023clinicaladvancesin pages 1-2, huang2025advancingobsessive–compulsivedisorder pages 1-2).
Neurosurgical Interventions: Ablative procedures such as anterior cingulotomy are reserved for severe, treatment-refractory cases (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
Staged-care models match treatment intensity to illness severity, comorbidity burden, and prior treatment response. This approach aims to deliver "right care, first time" and close treatment gaps (farrell2023closingthegap pages 1-2).
Suggested MAXO Terms: - MAXO:0000011 (Psychotherapy) - MAXO:0000058 (Pharmacotherapy) - MAXO:0001298 (Cognitive behavioral therapy)
| Treatment Category | Specific Interventions | Mechanism of Action | Evidence Level | Efficacy/Response Rates | Key Citations |
|---|---|---|---|---|---|
| First-line psychotherapy | Cognitive behavioral therapy with exposure and response prevention (CBT-ERP); individual, family-based, group, internet/digital, and staged-care CBT-ERP for youth | Repeated, systematic exposure to obsessional triggers with prevention of rituals/avoidance; promotes inhibitory learning, fear extinction, reduced negative reinforcement, and improved cognitive control over compulsions | High; described as gold-standard/first-line in recent reviews and guidelines | Strong efficacy across adults and youth; not all patients remit, and a substantial minority remain symptomatic; pediatric review notes CBT-ERP is highly effective, though underused in practice; adherence during ERP predicts better short- and long-term outcomes (roh2023clinicaladvancesin pages 1-2, farrell2023closingthegap pages 1-2) | (roh2023clinicaladvancesin pages 1-2, farrell2023closingthegap pages 1-2) |
| First-line pharmacotherapy | Selective serotonin reuptake inhibitors (SSRIs): fluoxetine, sertraline, fluvoxamine, paroxetine, escitalopram/citalopram (class-level evidence emphasized) | Block serotonin reuptake, increasing synaptic serotonin; downstream modulation of cortico-striato-thalamo-cortical (CSTC) circuit activity and symptom-related salience processing | High; consistently recommended as first-line pharmacotherapy in adult OCD reviews | Effective for many patients, but a large proportion show only partial response; one 2025 review cited in retrieved evidence notes ~50% may not respond adequately to standard treatments; SSRIs and CBT both reduce symptoms, with partly distinct neural effects and common reduction of insula activity during symptom provocation after treatment (roh2023clinicaladvancesin pages 1-2, huang2025advancingobsessive–compulsivedisorder pages 1-2) | (roh2023clinicaladvancesin pages 1-2, huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Combined first-line treatment | CBT-ERP plus SSRI, especially for moderate-severe illness, comorbidity, or partial response to monotherapy | Combines behavioral extinction/response prevention with serotonergic modulation of CSTC dysfunction | Moderate-high; recommended in treatment overviews and staged-care models | Used when symptom burden, comorbidity, or prior treatment history justify escalation; recent pediatric staged-care framework recommends matching intensity to severity and previous response rather than one-size-fits-all care (roh2023clinicaladvancesin pages 1-2, farrell2023closingthegap pages 1-2) | (roh2023clinicaladvancesin pages 1-2, farrell2023closingthegap pages 1-2) |
| Second-line / augmentation | Atypical antipsychotic augmentation of SSRIs (class-level; e.g., risperidone/aripiprazole commonly referenced in OCD practice reviews), especially for SSRI partial responders or tic-related presentations | Dopamine/serotonin receptor modulation; intended to reduce persistent compulsivity and augment SSRI effect in refractory CSTC dysfunction | Moderate; recommended in adult treatment reviews as augmentation rather than monotherapy | Useful in a subset of partial responders; evidence supports use after adequate SSRI trial and/or CBT failure rather than as initial treatment (roh2023clinicaladvancesin pages 1-2) | (roh2023clinicaladvancesin pages 1-2) |
| Second-line / treatment optimization | High-intensity or concentrated ERP; intensive outpatient/residential ERP; improving adherence and therapist fidelity | Increases exposure dose, reduces accommodation/avoidance, and strengthens ritual prevention in severe or chronic cases | Moderate; supported by clinical studies and service-model literature | Treatment adherence predicts post-treatment, 3-month, and 1-year OCD severity and work/social functioning in difficult-to-treat cases, suggesting optimization of ERP delivery is a key modifiable lever (farrell2023closingthegap pages 1-2) | (farrell2023closingthegap pages 1-2) |
| Novel / experimental neuromodulation | Repetitive transcranial magnetic stimulation (TMS), including circuit-targeted stimulation approaches | Noninvasive modulation of dysfunctional frontostriatal/CSTC activity, potentially affecting inhibition, salience, and compulsive motor patterns | Emerging/moderate; highlighted in recent reviews as promising but not universally first-line | Considered for refractory OCD; recent reviews frame TMS as a developing option alongside advances in neuroimaging/electrophysiology-guided personalization (roh2023clinicaladvancesin pages 1-2) | (roh2023clinicaladvancesin pages 1-2) |
| Novel / experimental neuromodulation | Deep brain stimulation (DBS) targeting CSTC-related nodes; ventral/striatal and related circuit targets discussed in recent reviews | Direct electrical modulation of pathologic frontostriatal network dynamics in severe, treatment-refractory OCD | Moderate for severe refractory illness; generally reserved for highly selected patients | Used after failure of standard therapies; recent modeling/review work emphasizes frontostriatal circuit rebalancing as the conceptual basis for benefit (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Neurosurgical interventions | Ablative neurosurgery/lesion procedures such as anterior cingulotomy or related psychosurgical approaches in extreme refractory cases | Interrupts maladaptive CSTC loops implicated in persistent obsessions/compulsions | Limited but established for rare, severe, otherwise intractable cases | Historical and contemporary literature cited in recent reviews indicates symptom improvement can occur in carefully selected severe cases; reserved for last-resort use due to invasiveness (jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | (jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Treatment resistance approaches | Personalized staged-care pathways; escalation based on severity, comorbidity, and prior treatment history; multimodal service design | Matches treatment intensity to illness stage and complexity; aims to reduce undertreatment and delayed access | Moderate; especially developed in pediatric OCD service literature | Proposed to close the “treatment gap” and “quality gap”; youth OCD often experiences long delays to care, and staged models aim to deliver the least intrusive effective intervention first, escalating as needed (farrell2023closingthegap pages 1-2, liu2023earlyidentificationand pages 1-2) | (farrell2023closingthegap pages 1-2, liu2023earlyidentificationand pages 1-2) |
| Treatment resistance approaches | Mechanism-informed monitoring with imaging/brain-based biomarkers (research use), and circuit-informed intervention selection | Uses neural signatures such as insula/frontostriatal activity to understand or predict response and tailor interventions | Emerging/experimental | 2024 longitudinal imaging study found CBT and SSRIs both reduced symptoms but produced partly divergent brain changes, with a common reduction in insula activity during symptom provocation; currently more useful mechanistically than diagnostically in routine care (roh2023clinicaladvancesin pages 1-2) | (roh2023clinicaladvancesin pages 1-2) |
Table: This table summarizes current OCD treatment strategies across first-line, second-line, experimental, and treatment-resistant settings. It highlights mechanisms, approximate evidence strength, and clinically relevant outcome patterns from recent reviews and studies.
Early identification and intervention in pediatric OCD is critical, as delayed treatment is associated with worse prognosis (liu2023earlyidentificationand pages 1-2). Interventions focus on preventing conversion of obsessive-compulsive symptoms into full-blown OCD (liu2023earlyidentificationand pages 1-2).
Focuses on alleviating mild to moderate OCD and preventing complications, though interventions for comorbidities remain in their infancy (liu2023earlyidentificationand pages 1-2).
Systematic screening programs for OCD are not currently widespread. The duration of untreated OCD remains among the highest of all psychiatric disorders, highlighting need for improved early detection (liu2023earlyidentificationand pages 1-2).
Limited information available in retrieved sources regarding naturally occurring OCD in other species.
Multiple transgenic mouse models have been developed to study OCD mechanisms (huang2025advancingobsessive–compulsivedisorder pages 1-2):
Key Mouse Models: - Hoxb8-KO: Excessive grooming/self-injury phenotype - Slc1a1-KO: Glutamatergic dysfunction model - Sapap3-KO: Well-established compulsive grooming model with corticostriatal synaptic abnormalities - Slitrk5-KO: Excessive grooming and anxiety-like behaviors - Spred2-KO: Repetitive grooming/compulsive-like behavior
Optogenetic stimulation of orbitofrontal cortex-ventromedial striatum (OFC-VMS) connections can induce OCD-like grooming behaviors in mice, supporting the CSTC circuit model (jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
Zebrafish models with altered slitrk5a demonstrate OCD-like "checking" behaviors, useful for high-throughput screening (huang2025advancingobsessive–compulsivedisorder pages 1-2).
No single model captures the full human OCD syndrome, particularly intrusive obsessions, symptom dimensions, fluctuating insight, and comorbidity patterns (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3).
| Model Type | Specific Model Name | Species | Genes Involved | OCD-like Phenotypes Observed | Brain Regions/Circuits Affected | Utility/Applications | Limitations |
|---|---|---|---|---|---|---|---|
| Genetic knockout | Hoxb8-KO | Mouse | Hoxb8 | Excessive grooming/self-injury–like repetitive behavior; compulsive grooming phenotype used as an OCD-relevant endophenotype | Cortico-striato-thalamo-cortical (CSTC)-relevant circuitry broadly implicated; also linked to microglial/hematopoietic contributions rather than a single canonical OCD node (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Useful for studying repetitive grooming, neuroimmune contributions, and disentangling compulsive motor output from anxiety-like behaviors (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Face validity for grooming is strong, but limited construct validity for intrusive obsessions; captures only a subset of human OCD phenomenology (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Genetic knockout | Slc1a1-KO | Mouse | Slc1a1 / EAAT3 | Repetitive/compulsive-like behaviors and anxiety-related phenotypes in an OCD risk-gene framework | Glutamatergic signaling within CSTC-related circuits; striatum/cortex glutamate homeostasis is the main mechanistic relevance (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | Useful for probing glutamatergic mechanisms and testing candidate glutamate-modulating interventions (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | Human OCD is polygenic; single-gene knockout incompletely models symptom heterogeneity and cognitive obsessions (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Genetic knockout | Sapap3-KO | Mouse | Sapap3 / Dlgap3 | Excessive grooming, anxiety-like behavior, repetitive acts; one of the best-established compulsive grooming models | Corticostriatal synapses, especially striatal dysfunction within CSTC circuitry (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | High translational value for corticostriatal synaptopathy, habit/compulsivity mechanisms, and rescue experiments with circuit or pharmacologic interventions (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Strong for compulsions/grooming but does not model intrusive obsessions or full symptom dimensions seen in humans (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Genetic knockout | Slitrk5-KO | Mouse | Slitrk5 | Excessive grooming and anxiety-like/compulsive-like behaviors | Orbitofrontal-striatal and broader CSTC dysfunction relevant to compulsivity (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | Useful for studying synaptogenesis-related mechanisms and corticostriatal abnormalities in OCD-like behavior (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Limited to a narrow behavioral phenotype; genetic effect sizes in humans are smaller and more polygenic than in knockout models (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Genetic knockout | Spred2-KO | Mouse | Spred2 | Repetitive grooming/compulsive-like behavior in transgenic OCD modeling summaries | CSTC-related signaling abnormalities; mechanistically linked to intracellular signaling regulation rather than a single OCD-specific node (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Useful for investigating intracellular signaling contributions to repetitive behavior and for comparative model selection across transgenic strains (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Less extensively validated than Sapap3-KO; uncertain breadth of translational relevance to diverse OCD symptom dimensions (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Genetic/optogenetic circuit model | Repeated OFC–VMS stimulation model | Mouse | Circuit perturbation model rather than a single gene | Induced OCD-like grooming/compulsive behavior after repeated stimulation | Orbitofrontal cortex (OFC) and ventromedial striatum (VMS) within CSTC loops (jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | Strong causal tool for testing whether abnormal CSTC activity can generate compulsive behaviors; valuable for circuit-level intervention studies (jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | Not a natural disease model; limited ecological validity and does not capture developmental/polygenic aspects of OCD (jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Transgenic model class | Knockout mouse models (aggregate class reviewed in recent literature) | Mouse | Includes Hoxb8, Slc1a1, Sapap3, Slitrk5, Spred2 | Repetitive grooming, anxiety-like behavior, compulsive-like rituals; model-specific variation | Recurrently implicate CSTC circuits, especially orbitofrontal, striatal, and thalamic pathway abnormalities (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) | Comparative platform for selecting models by mechanism: synaptic, glutamatergic, signaling, or neuroimmune hypotheses; supports neuromodulation and drug development work (huang2025advancingobsessive–compulsivedisorder pages 1-2) | No single model captures the full human syndrome, especially obsessions, symptom dimensions, fluctuating insight, and comorbidity (huang2025advancingobsessive–compulsivedisorder pages 1-2, jalal2023obsessive‐compulsivedisorderetiology pages 2-3) |
| Zebrafish genetic model | slitrk5a altered zebrafish model | Zebrafish | slitrk5a | “Checking”-like repetitive behavior reported as OCD-like in zebrafish model literature | Vertebrate brain circuit analogs relevant to repetitive behavioral control; not directly homologous to mammalian CSTC architecture (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Useful for high-throughput genetics and drug screening, rapid developmental studies, and comparative validation of OCD risk genes (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Behavioral homology to human obsessions/compulsions is indirect; circuit correspondence to human OCD is limited (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Other species/model note | Zebrafish and other lower-animal OCD-relevant models (general mention) | Zebrafish / lower vertebrates | Varies by construct | Repetitive/compulsive-like phenotypes are used as analog readouts | Developmental and conserved neural pathway studies; not direct one-to-one CSTC replication (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Helpful for scalable screening and testing conserved gene-function effects across species (huang2025advancingobsessive–compulsivedisorder pages 1-2) | Reduced face validity for complex human psychopathology, especially intrusive thoughts and higher-order cognition (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
| Pharmacological / environmental models | Not specified in the available OCD contexts | Not specified | Not specified | Typically used in the field for repetitive behavior provocation, but no specific OCD pharmacological model was detailed in the available contexts | Not specified in available contexts | Can complement genetic models when available | Not enough source detail in the available contexts to summarize specific models responsibly (huang2025advancingobsessive–compulsivedisorder pages 1-2) |
Table: This table summarizes major animal models used in obsessive-compulsive disorder research, emphasizing transgenic mouse lines and zebrafish models mentioned in the available sources. It is useful for comparing each model’s phenotypes, implicated circuits, translational uses, and major limitations.
Obsessive-Compulsive Disorder is a common, chronic neuropsychiatric disorder affecting 1-3% of the population with onset typically in childhood, adolescence, or young adulthood. The condition demonstrates substantial heritability (27-47% in adults, 45-65% in children) with highly polygenic architecture involving thousands of genetic variants. The largest GWAS identified 30 genome-wide significant loci and prioritized key genes including WDR6, DALRD3, and CTNND1.
OCD pathophysiology centers on dysfunction in cortico-striato-thalamo-cortical (CSTC) circuits involving orbitofrontal cortex, anterior cingulate cortex, striatum, and thalamus, with dysregulation of serotonergic, dopaminergic, and glutamatergic neurotransmission. Genetic risk is enriched in excitatory neurons of hippocampus and cortex, and dopamine receptor-containing medium spiny neurons in striatum.
First-line treatments include cognitive behavioral therapy with exposure and response prevention (CBT-ERP) and selective serotonin reuptake inhibitors (SSRIs), though approximately 50% of patients show inadequate response to initial interventions. Novel treatments include neuromodulation (TMS, DBS) for refractory cases. Staged-care models aim to match treatment intensity to clinical severity and prior response.
OCD causes substantial functional impairment and disability, with only 19.8% of affected individuals receiving treatment in the past year globally. Early identification and intervention are critical, particularly in pediatric-onset cases which demonstrate higher genetic loading and potentially worse prognosis without adequate treatment.
References
(jalal2023obsessive‐compulsivedisorderetiology pages 1-2): Baland Jalal, Samuel R. Chamberlain, and Barbara J. Sahakian. Obsessive‐compulsive disorder: etiology, neuropathology, and cognitive dysfunction. Brain and Behavior, May 2023. URL: https://doi.org/10.1002/brb3.3000, doi:10.1002/brb3.3000. This article has 162 citations and is from a peer-reviewed journal.
(roh2023clinicaladvancesin pages 1-2): Daeyoung Roh, Ki Won Jang, and Chan-Hyung Kim. Clinical advances in treatment strategies for obsessive-compulsive disorder in adults. Clinical Psychopharmacology and Neuroscience, 21:676-685, Jul 2023. URL: https://doi.org/10.9758/cpn.23.1075, doi:10.9758/cpn.23.1075. This article has 29 citations.
(stein2025obsessivecompulsivedisorderin pages 1-2): Dan J. Stein, Ayelet Meron Ruscio, Yasmin Altwaijri, Wai Tat Chiu, Nancy A. Sampson, Sergio Aguilar-Gaxiola, Ali Al-Hamzawi, Jordi Alonso, Stephanie Chardoul, Oye Gureje, Chiyi Hu, Elie G. Karam, John J. McGrath, Fernando Navarro-Mateu, Kate M. Scott, Juan Carlos Stagnaro, Yolanda Torres, Cristian Vladescu, Jacek Wciórka, Miguel Xavier, Ronald C. Kessler, Yasmin A. Altwaijri, Laura Helena Andrade, Lukoye Atwoli, Corina Benjet, Guilherme Borges, Ronny Bruffaerts, Brendan Bunting, Jose Miguel Caldas-de-Almeida, Graça Cardoso, Louisa Degenhardt, Giovanni de Girolamo, Josep Maria Haro, Meredith G. Harris, Hristo Hinkov, Chiyi Hu, Peter de Jonge, Aimee Nasser Karam, Georges Karam, Alan E. Kazdin, Norito Kawakami, Andrzej Kiejna, Viviane Kovess-Masfety, Maria Elena Medina-Mora, Jacek Moskalewicz, Daisuke Nishi, Marina Piazza, José Posada-Villa, Annelieke Roest, Margreet ten Have, Nathan Tintle, Maria Carmen Viana, Daniel V. Vigo, David R. Williams, Bogdan Wojtyniak, and Alan M. Zaslavsky. Obsessive-compulsive disorder in the world mental health surveys. BMC Medicine, Jul 2025. URL: https://doi.org/10.1186/s12916-025-04209-5, doi:10.1186/s12916-025-04209-5. This article has 41 citations and is from a domain leading peer-reviewed journal.
(strom2025genomewideanalysesidentify pages 1-2): Nora I. Strom, Zachary F. Gerring, Marco Galimberti, Dongmei Yu, Matthew W. Halvorsen, Abdel Abdellaoui, Cristina Rodriguez-Fontenla, Julia M. Sealock, Tim Bigdeli, Jonathan R. Coleman, Behrang Mahjani, Jackson G. Thorp, Katharina Bey, Christie L. Burton, Jurjen J. Luykx, Gwyneth Zai, Silvia Alemany, Christine Andre, Kathleen D. Askland, Julia Bäckman, Nerisa Banaj, Cristina Barlassina, Judith Becker Nissen, O. Joseph Bienvenu, Donald Black, Michael H. Bloch, Sigrid Børte, Rosa Bosch, Michael Breen, Brian P. Brennan, Helena Brentani, Joseph D. Buxbaum, Jonas Bybjerg-Grauholm, Enda M. Byrne, Judit Cabana-Dominguez, Beatriz Camarena, Adrian Camarena, Carolina Cappi, Angel Carracedo, Miguel Casas, Maria Cristina Cavallini, Valentina Ciullo, Edwin H. Cook, Jesse Crosby, Bernadette A. Cullen, Elles J. De Schipper, Richard Delorme, Srdjan Djurovic, Jason A. Elias, Xavier Estivill, Martha J. Falkenstein, Bengt T. Fundin, Lauryn Garner, Christina Gironda, Fernando S. Goes, Marco A. Grados, Jakob Grove, Wei Guo, Jan Haavik, Kristen Hagen, Kelly Harrington, Alexandra Havdahl, Kira D. Höffler, Ana G. Hounie, Donald Hucks, Christina Hultman, Magdalena Janecka, Eric Jenike, Elinor K. Karlsson, Kara Kelley, Julia Klawohn, Janice E. Krasnow, Kristi Krebs, Christoph Lange, Nuria Lanzagorta, Daniel Levey, Kerstin Lindblad-Toh, Fabio Macciardi, Brion Maher, Brittany Mathes, Evonne McArthur, Nathaniel McGregor, Nicole C. McLaughlin, Sandra Meier, Euripedes C. Miguel, Maureen Mulhern, Paul S. Nestadt, Erika L. Nurmi, Kevin S. O’Connell, Lisa Osiecki, Olga Therese Ousdal, Teemu Palviainen, Nancy L. Pedersen, Fabrizio Piras, Federica Piras, Sriramya Potluri, Raquel Rabionet, Alfredo Ramirez, Scott Rauch, Abraham Reichenberg, Mark A. Riddle, Stephan Ripke, Maria C. Rosário, Aline S. Sampaio, Miriam A. Schiele, Anne Heidi Skogholt, Laura G. Sloofman, Jan Smit, María Soler Artigas, Laurent F. Thomas, Eric Tifft, Homero Vallada, Nathanial van Kirk, Jeremy Veenstra-VanderWeele, Nienke N. Vulink, Christopher P. Walker, Ying Wang, Jens R. Wendland, Bendik S. Winsvold, Yin Yao, Hang Zhou, Andres Metspalu, Tõnu Esko, Reedik Mägi, Mari Nelis, Georgi Hudjashov, Chris German, Arpana Agrawal, Pino Alonso, Götz Berberich, Kathleen K. Bucholz, Cynthia M. Bulik, Danielle Cath, Damiaan Denys, Valsamma Eapen, Howard Edenberg, Peter Falkai, Thomas V. Fernandez, Abby J. Fyer, J. M. Gaziano, Dan A. Geller, Hans J. Grabe, Benjamin D. Greenberg, Gregory L. Hanna, Ian B. Hickie, David M. Hougaard, Norbert Kathmann, James Kennedy, Dongbing Lai, Mikael Landén, Stéphanie Le Hellard, Marion Leboyer, Christine Lochner, James T. McCracken, Sarah E. Medland, Preben B. Mortensen, Benjamin M. Neale, Humberto Nicolini, Merete Nordentoft, Michele Pato, Carlos Pato, David L. Pauls, John Piacentini, Christopher Pittenger, Danielle Posthuma, Josep Antoni Ramos-Quiroga, Steven A. Rasmussen, Margaret A. Richter, David R. Rosenberg, Stephan Ruhrmann, Jack F. Samuels, Sven Sandin, Paul Sandor, Gianfranco Spalletta, Dan J. Stein, S. Evelyn Stewart, Eric A. Storch, Barbara E. Stranger, Maurizio Turiel, Thomas Werge, Ole A. Andreassen, Anders D. Børglum, Susanne Walitza, Kristian Hveem, Bjarne K. Hansen, Christian Rück, Nicholas G. Martin, Lili Milani, Ole Mors, Ted Reichborn-Kjennerud, Marta Ribasés, Gerd Kvale, David Mataix-Cols, Katharina Domschke, Edna Grünblatt, Michael Wagner, John-Anker Zwart, Gerome Breen, Gerald Nestadt, Jaakko Kaprio, Paul D. Arnold, Dorothy E. Grice, James A. Knowles, Helga Ask, Karin J. Verweij, Lea K. Davis, Dirk J. Smit, James J. Crowley, Jeremiah M. Scharf, Murray B. Stein, Joel Gelernter, Carol A. Mathews, Eske M. Derks, and Manuel Mattheisen. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder. Nature Genetics, 57:1389-1401, May 2025. URL: https://doi.org/10.1038/s41588-025-02189-z, doi:10.1038/s41588-025-02189-z. This article has 70 citations and is from a highest quality peer-reviewed journal.
(jalal2023obsessive‐compulsivedisorderetiology pages 2-3): Baland Jalal, Samuel R. Chamberlain, and Barbara J. Sahakian. Obsessive‐compulsive disorder: etiology, neuropathology, and cognitive dysfunction. Brain and Behavior, May 2023. URL: https://doi.org/10.1002/brb3.3000, doi:10.1002/brb3.3000. This article has 162 citations and is from a peer-reviewed journal.
(dhiman2025hereditarypatternsand pages 1-1): Abhinay Dhiman, Sidharth Mehan, Zuber Khan, Aarti Tiwari, Ghanshyam Das Gupta, and Acharan Singh Narula. Hereditary patterns and genetic associations in obsessive-compulsive disorder (ocd): neuropsychiatric insights, genetic influences, and treatment perspectives. Mar 2025. URL: https://doi.org/10.2174/0115665232316708240828063527, doi:10.2174/0115665232316708240828063527. This article has 8 citations and is from a peer-reviewed journal.
(liu2023earlyidentificationand pages 1-2): Xingyu Liu and Qing Fan. Early identification and intervention in pediatric obsessive-compulsive disorder. Brain Sciences, 13:399, Feb 2023. URL: https://doi.org/10.3390/brainsci13030399, doi:10.3390/brainsci13030399. This article has 25 citations.
(strom2025genomewideanalysesidentify pages 2-3): Nora I. Strom, Zachary F. Gerring, Marco Galimberti, Dongmei Yu, Matthew W. Halvorsen, Abdel Abdellaoui, Cristina Rodriguez-Fontenla, Julia M. Sealock, Tim Bigdeli, Jonathan R. Coleman, Behrang Mahjani, Jackson G. Thorp, Katharina Bey, Christie L. Burton, Jurjen J. Luykx, Gwyneth Zai, Silvia Alemany, Christine Andre, Kathleen D. Askland, Julia Bäckman, Nerisa Banaj, Cristina Barlassina, Judith Becker Nissen, O. Joseph Bienvenu, Donald Black, Michael H. Bloch, Sigrid Børte, Rosa Bosch, Michael Breen, Brian P. Brennan, Helena Brentani, Joseph D. Buxbaum, Jonas Bybjerg-Grauholm, Enda M. Byrne, Judit Cabana-Dominguez, Beatriz Camarena, Adrian Camarena, Carolina Cappi, Angel Carracedo, Miguel Casas, Maria Cristina Cavallini, Valentina Ciullo, Edwin H. Cook, Jesse Crosby, Bernadette A. Cullen, Elles J. De Schipper, Richard Delorme, Srdjan Djurovic, Jason A. Elias, Xavier Estivill, Martha J. Falkenstein, Bengt T. Fundin, Lauryn Garner, Christina Gironda, Fernando S. Goes, Marco A. Grados, Jakob Grove, Wei Guo, Jan Haavik, Kristen Hagen, Kelly Harrington, Alexandra Havdahl, Kira D. Höffler, Ana G. Hounie, Donald Hucks, Christina Hultman, Magdalena Janecka, Eric Jenike, Elinor K. Karlsson, Kara Kelley, Julia Klawohn, Janice E. Krasnow, Kristi Krebs, Christoph Lange, Nuria Lanzagorta, Daniel Levey, Kerstin Lindblad-Toh, Fabio Macciardi, Brion Maher, Brittany Mathes, Evonne McArthur, Nathaniel McGregor, Nicole C. McLaughlin, Sandra Meier, Euripedes C. Miguel, Maureen Mulhern, Paul S. Nestadt, Erika L. Nurmi, Kevin S. O’Connell, Lisa Osiecki, Olga Therese Ousdal, Teemu Palviainen, Nancy L. Pedersen, Fabrizio Piras, Federica Piras, Sriramya Potluri, Raquel Rabionet, Alfredo Ramirez, Scott Rauch, Abraham Reichenberg, Mark A. Riddle, Stephan Ripke, Maria C. Rosário, Aline S. Sampaio, Miriam A. Schiele, Anne Heidi Skogholt, Laura G. Sloofman, Jan Smit, María Soler Artigas, Laurent F. Thomas, Eric Tifft, Homero Vallada, Nathanial van Kirk, Jeremy Veenstra-VanderWeele, Nienke N. Vulink, Christopher P. Walker, Ying Wang, Jens R. Wendland, Bendik S. Winsvold, Yin Yao, Hang Zhou, Andres Metspalu, Tõnu Esko, Reedik Mägi, Mari Nelis, Georgi Hudjashov, Chris German, Arpana Agrawal, Pino Alonso, Götz Berberich, Kathleen K. Bucholz, Cynthia M. Bulik, Danielle Cath, Damiaan Denys, Valsamma Eapen, Howard Edenberg, Peter Falkai, Thomas V. Fernandez, Abby J. Fyer, J. M. Gaziano, Dan A. Geller, Hans J. Grabe, Benjamin D. Greenberg, Gregory L. Hanna, Ian B. Hickie, David M. Hougaard, Norbert Kathmann, James Kennedy, Dongbing Lai, Mikael Landén, Stéphanie Le Hellard, Marion Leboyer, Christine Lochner, James T. McCracken, Sarah E. Medland, Preben B. Mortensen, Benjamin M. Neale, Humberto Nicolini, Merete Nordentoft, Michele Pato, Carlos Pato, David L. Pauls, John Piacentini, Christopher Pittenger, Danielle Posthuma, Josep Antoni Ramos-Quiroga, Steven A. Rasmussen, Margaret A. Richter, David R. Rosenberg, Stephan Ruhrmann, Jack F. Samuels, Sven Sandin, Paul Sandor, Gianfranco Spalletta, Dan J. Stein, S. Evelyn Stewart, Eric A. Storch, Barbara E. Stranger, Maurizio Turiel, Thomas Werge, Ole A. Andreassen, Anders D. Børglum, Susanne Walitza, Kristian Hveem, Bjarne K. Hansen, Christian Rück, Nicholas G. Martin, Lili Milani, Ole Mors, Ted Reichborn-Kjennerud, Marta Ribasés, Gerd Kvale, David Mataix-Cols, Katharina Domschke, Edna Grünblatt, Michael Wagner, John-Anker Zwart, Gerome Breen, Gerald Nestadt, Jaakko Kaprio, Paul D. Arnold, Dorothy E. Grice, James A. Knowles, Helga Ask, Karin J. Verweij, Lea K. Davis, Dirk J. Smit, James J. Crowley, Jeremiah M. Scharf, Murray B. Stein, Joel Gelernter, Carol A. Mathews, Eske M. Derks, and Manuel Mattheisen. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder. Nature Genetics, 57:1389-1401, May 2025. URL: https://doi.org/10.1038/s41588-025-02189-z, doi:10.1038/s41588-025-02189-z. This article has 70 citations and is from a highest quality peer-reviewed journal.
(strom2025genomewideanalysesidentify pages 3-4): Nora I. Strom, Zachary F. Gerring, Marco Galimberti, Dongmei Yu, Matthew W. Halvorsen, Abdel Abdellaoui, Cristina Rodriguez-Fontenla, Julia M. Sealock, Tim Bigdeli, Jonathan R. Coleman, Behrang Mahjani, Jackson G. Thorp, Katharina Bey, Christie L. Burton, Jurjen J. Luykx, Gwyneth Zai, Silvia Alemany, Christine Andre, Kathleen D. Askland, Julia Bäckman, Nerisa Banaj, Cristina Barlassina, Judith Becker Nissen, O. Joseph Bienvenu, Donald Black, Michael H. Bloch, Sigrid Børte, Rosa Bosch, Michael Breen, Brian P. Brennan, Helena Brentani, Joseph D. Buxbaum, Jonas Bybjerg-Grauholm, Enda M. Byrne, Judit Cabana-Dominguez, Beatriz Camarena, Adrian Camarena, Carolina Cappi, Angel Carracedo, Miguel Casas, Maria Cristina Cavallini, Valentina Ciullo, Edwin H. Cook, Jesse Crosby, Bernadette A. Cullen, Elles J. De Schipper, Richard Delorme, Srdjan Djurovic, Jason A. Elias, Xavier Estivill, Martha J. Falkenstein, Bengt T. Fundin, Lauryn Garner, Christina Gironda, Fernando S. Goes, Marco A. Grados, Jakob Grove, Wei Guo, Jan Haavik, Kristen Hagen, Kelly Harrington, Alexandra Havdahl, Kira D. Höffler, Ana G. Hounie, Donald Hucks, Christina Hultman, Magdalena Janecka, Eric Jenike, Elinor K. Karlsson, Kara Kelley, Julia Klawohn, Janice E. Krasnow, Kristi Krebs, Christoph Lange, Nuria Lanzagorta, Daniel Levey, Kerstin Lindblad-Toh, Fabio Macciardi, Brion Maher, Brittany Mathes, Evonne McArthur, Nathaniel McGregor, Nicole C. McLaughlin, Sandra Meier, Euripedes C. Miguel, Maureen Mulhern, Paul S. Nestadt, Erika L. Nurmi, Kevin S. O’Connell, Lisa Osiecki, Olga Therese Ousdal, Teemu Palviainen, Nancy L. Pedersen, Fabrizio Piras, Federica Piras, Sriramya Potluri, Raquel Rabionet, Alfredo Ramirez, Scott Rauch, Abraham Reichenberg, Mark A. Riddle, Stephan Ripke, Maria C. Rosário, Aline S. Sampaio, Miriam A. Schiele, Anne Heidi Skogholt, Laura G. Sloofman, Jan Smit, María Soler Artigas, Laurent F. Thomas, Eric Tifft, Homero Vallada, Nathanial van Kirk, Jeremy Veenstra-VanderWeele, Nienke N. Vulink, Christopher P. Walker, Ying Wang, Jens R. Wendland, Bendik S. Winsvold, Yin Yao, Hang Zhou, Andres Metspalu, Tõnu Esko, Reedik Mägi, Mari Nelis, Georgi Hudjashov, Chris German, Arpana Agrawal, Pino Alonso, Götz Berberich, Kathleen K. Bucholz, Cynthia M. Bulik, Danielle Cath, Damiaan Denys, Valsamma Eapen, Howard Edenberg, Peter Falkai, Thomas V. Fernandez, Abby J. Fyer, J. M. Gaziano, Dan A. Geller, Hans J. Grabe, Benjamin D. Greenberg, Gregory L. Hanna, Ian B. Hickie, David M. Hougaard, Norbert Kathmann, James Kennedy, Dongbing Lai, Mikael Landén, Stéphanie Le Hellard, Marion Leboyer, Christine Lochner, James T. McCracken, Sarah E. Medland, Preben B. Mortensen, Benjamin M. Neale, Humberto Nicolini, Merete Nordentoft, Michele Pato, Carlos Pato, David L. Pauls, John Piacentini, Christopher Pittenger, Danielle Posthuma, Josep Antoni Ramos-Quiroga, Steven A. Rasmussen, Margaret A. Richter, David R. Rosenberg, Stephan Ruhrmann, Jack F. Samuels, Sven Sandin, Paul Sandor, Gianfranco Spalletta, Dan J. Stein, S. Evelyn Stewart, Eric A. Storch, Barbara E. Stranger, Maurizio Turiel, Thomas Werge, Ole A. Andreassen, Anders D. Børglum, Susanne Walitza, Kristian Hveem, Bjarne K. Hansen, Christian Rück, Nicholas G. Martin, Lili Milani, Ole Mors, Ted Reichborn-Kjennerud, Marta Ribasés, Gerd Kvale, David Mataix-Cols, Katharina Domschke, Edna Grünblatt, Michael Wagner, John-Anker Zwart, Gerome Breen, Gerald Nestadt, Jaakko Kaprio, Paul D. Arnold, Dorothy E. Grice, James A. Knowles, Helga Ask, Karin J. Verweij, Lea K. Davis, Dirk J. Smit, James J. Crowley, Jeremiah M. Scharf, Murray B. Stein, Joel Gelernter, Carol A. Mathews, Eske M. Derks, and Manuel Mattheisen. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder. Nature Genetics, 57:1389-1401, May 2025. URL: https://doi.org/10.1038/s41588-025-02189-z, doi:10.1038/s41588-025-02189-z. This article has 70 citations and is from a highest quality peer-reviewed journal.
(farrell2023closingthegap pages 1-2): Lara J. Farrell, Allison M. Waters, Eric A. Storch, Gabrielle Simcock, Iain E. Perkes, Jessica R. Grisham, Katelyn M. Dyason, and Thomas H. Ollendick. Closing the gap for children with ocd: a staged-care model of cognitive behavioural therapy with exposure and response prevention. Clinical Child and Family Psychology Review, 26:642-664, Jul 2023. URL: https://doi.org/10.1007/s10567-023-00439-2, doi:10.1007/s10567-023-00439-2. This article has 32 citations and is from a domain leading peer-reviewed journal.
(huang2025advancingobsessive–compulsivedisorder pages 1-2): Xinyuejia Huang, Linglong Xiao, Mengqi Wang, Yang Wu, Hao Deng, and Wei Wang. Advancing obsessive–compulsive disorder research: insights from transgenic animal models and innovative therapies. Brain Sciences, 15:43, Jan 2025. URL: https://doi.org/10.3390/brainsci15010043, doi:10.3390/brainsci15010043. This article has 1 citations.